 
J1H-MC-LAJB(b) Clinical Protocol  
  A Phase 2, Randomized, Double-Blind, Placebo -Controlled Study of LY3451838 in Adults With 
Treatment- Resistant Migraine 
 
 
[STUDY_ID_REMOVED]   Approval Date: 19-Nov -2021 
J1H-MC-LAJB( b)Clinical Protocol Page 1
LY3451838Protocol J1H -MC-LAJB(b)
A Phase 2, Randomized, Double -Blind, Placebo -Controlled 
Study  of LY3451838 in A dults with Treatment -Resistant 
Migraine
Confidential Information
The information contained in this document is confidential and is intended for the use of 
clinical investigators. It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copi[INVESTIGATOR_229154]3451838, unless such persons are bound by a confidentiality agreement with Eli Lilly 
and Company or its subsidiaries. 
Note to Regulatory Authorities: This document may contain protected personal data 
and/or commercially confidential information exempt from public disclosure. Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release. In 
the [LOCATION_002], this document is subject to Freedom of Information Act (FOIA) 
Exemption 4 and may not be reproduced or otherwise disseminated without the written 
approval of Eli Lilly and Company or its subsidiaries.
LY3451838
Eli Lilly and Company
Indianapolis, Indiana [LOCATION_003] [ZIP_CODE]
Protocol Electronically Signed and Approved by [CONTACT_11007] : 20 January 2020
Protocol Amendment (a) Electronically Signed and Approved by [CONTACT_11007]:  22 July 2020
Amendm ent (b) Electronically Signed and Approved by [CONTACT_57968].
Approval Date: 19-Nov-2021 GMT
J1H-MC-LAJB( b)Clinical Protocol Page 2
LY3451838Table of Contents
Section Page
Protocol  J1H-MC-LAJB(b) A Phase 2, Rando mized, Double -Blind, 
Placebo -Controlled Study  of LY3451838 in Adults with Treatment -
Resistant Migraine .............................................................................................................. [ADDRESS_275713] ivities....................................................................................................... 10
3. Introduction ...................................................................................................................... 14
3.1. Study  Rati onale ............................................................................................................ 14
3.2. Backgro und.................................................................................................................. 14
3.3 Benefit/Risk Assessment .............................................................................................. [ADDRESS_275714] ions.................................................................................................... 26
6.4. Screen Failures ............................................................................................................. 26
7. Treatments ........................................................................................................................ 28
7.1. Treatments Admi nistered ............................................................................................. 28
7.1.1. Packaging and Labelling ...................................................................................... 28
7.2. Method of Treatment Assignment ................................................................................ 29
7.2.1. Selection and Timing o f Doses ............................................................................. 29
7.3. Blinding ....................................................................................................................... 29
7.4. Dosage Modification .................................................................................................... 30
7.5. Preparati on/Handling/Storage/Accountabilit y............................................................... 30
7.6. Speci al Treatm ent Consi derat ions................................................................................ 30
7.6.1. Management of Infusio n Reactions ...................................................................... 30
7.7. Treatment Compliance .................................................................................................31
7.8. Concomitant Therapy ................................................................................................... 31
J1H-MC-LAJB( b)Clinical Protocol Page [ADDRESS_275715] to Follow -Up........................................................................................................ 34
9. Study  Assessments and Procedures ................................................................................... 35
9.1. Efficacy Assessments ................................................................................................... 35
9.1.1. Primary Efficacy  Assessments ............................................................................. 35
9.1.2. Secondary  Efficacy  Assessments .......................................................................... 35
9.1.3. Appropriateness of Assessments .......................................................................... 35
9.2. Adverse Events ............................................................................................................ 35
9.2.1. Adverse Event Moni toring wi th a System atic Questionnaire ................................ 36
9.2.2. Serious Adverse Events ........................................................................................ 36
[IP_ADDRESS]. Suspected Unexpected Serious Adverse React ions.......................................... 37
9.2.3. Com plaint Handling ............................................................................................. 38
9.3. Treatment of Overdose .................................................................................................38
9.4. Safety........................................................................................................................... 38
9.4.1. Physical and Ne urological Examinat ions.............................................................. 38
9.4.2. Vital Signs ........................................................................................................... 38
9.4.3. Electrocardiograms .............................................................................................. 38
[IP_ADDRESS]. Digital Electrocardi ogram  Storage .................................................................. 39
9.4.4. Laboratory  Tests .................................................................................................. 39
9.4.5. Immunogenicit y Assessments .............................................................................. 39
9.4.6. Safety Moni toring ................................................................................................ 40
[IP_ADDRESS]. Hepati c Safet y Moni toring .............................................................................. 40
[IP_ADDRESS]. Vasculit is........................................................................................................ 40
[IP_ADDRESS]. Hypersensi tivity Reacti on............................................................................... 41
[IP_ADDRESS]. Infusio n React ion........................................................................................... 42
[IP_ADDRESS]. Suicidal  Ideat ion and Behavior Risk Monitoring ............................................. 42
[IP_ADDRESS]. Cogni tion........................................................................................................ 42
9.5. Pharmacokinet ics......................................................................................................... 43
9.5.1. Bioanalysis ........................................................................................................... 43
9.6. Pharmacod ynamics ...................................................................................................... 43
9.6.1. Exploratory  Assessment of PACAP Concentrations ............................................. 43
9.7. Genet ics....................................................................................................................... 43
9.7.1. Who le Blood S ample for Pharm acogenet ic Research ........................................... 43
J1H-MC-LAJB( b)Clinical Protocol Page [ADDRESS_275716] ical Considerat ions........................................................................ 47
10.3.2. Treatment Group Comparabilit y........................................................................... 47
[IP_ADDRESS]. Patient Disposi tion.......................................................................................... 47
[IP_ADDRESS]. Patient Characteri stics.................................................................................... 47
[IP_ADDRESS]. Concomitant Therapy ..................................................................................... 48
[IP_ADDRESS]. Treatment Compliance .................................................................................... 48
10.3.3. Efficacy Analyses ................................................................................................ 48
[IP_ADDRESS]. Primary Analyses ........................................................................................... 48
[IP_ADDRESS]. Secondary  Analyses ........................................................................................ 48
[IP_ADDRESS]. Exploratory  Analyses ..................................................................................... 48
10.3.4. Safety Analyses .................................................................................................... 48
10.3.5. Pharmacokinet ic/Pharmacodynamic Analyses ...................................................... 49
[IP_ADDRESS]. Pharmacokinet ic Analyses .............................................................................. 49
[IP_ADDRESS]. Exploratory  Pharmacodynamic Analyses ........................................................ 49
10.3.6. Evaluat ion of Immunogenicit y............................................................................. 49
10.3.7. Other Analyses ..................................................................................................... 50
[IP_ADDRESS]. Health Economics ........................................................................................... 50
[IP_ADDRESS]. Analysis of C -SSRS Data ............................................................................... 50
10.3.8. Interim Analyses .................................................................................................. 50
11. References ........................................................................................................................ 51
12. Appendices ....................................................................................................................... 54
J1H-MC-LAJB( b)Clinical Protocol Page [ADDRESS_275717] ivities.................................................................................... 11
Table LAJB 7.1 Treat ments Allowed and Treatments Not Allowed as Conco mitant 
Therapy ......................................................................................................... 31
Table LAJB 12.1 Treatments Allowed and Treatments Not Allowed as C onco mitant 
Therapy ......................................................................................................... 70
J1H-MC-LAJB( b)Clinical Protocol Page [ADDRESS_275718] of Figures
Figure Page
Figure LAJB 5.1 Illustrati on of  study  design for Clinical Protocol J1H -MC-LAJB. .................. 19
J1H-MC-LAJB( b)Clinical Protocol Page [ADDRESS_275719] ing for Hypersensit ivity Events..................... 65
Appendix 6. Migraine and Headache Endpo int Definit ions................................................ 67
Appendix 7. Protocol  Amendment J1H -MC-LAJB(b) Summary ........................................ 68
J1H-MC-LAJB( b)Clinical Protocol Page 8
LY34518381.Synopsis
Title of Study:
A Phase 2, randomized, double -blind, pl acebo -controlled study of LY3451838 in adults with 
treatm ent-resistant migraine.
Rationale: 
LY3451838 is a fully human imm unogl obulin G (IgG4- variant monoclonal ant ibody ) that 
potently  and select ively binds and neutralizes pi[INVESTIGATOR_229155] -activating polypeptide 
(PACAP). Evidence suggests that PACAP -[ADDRESS_275720] asma PACAP l evels are elevated during a migraine attack. The objective of the 
Study  J1H-MC-LAJB (LAJB hereafter) is to evaluate the safet y and efficacy  of LY3451838 to 
placebo in a treatm ent-resistant, adul t pati ent populat ion with epi[INVESTIGATOR_39751] c or chroni c migraine. 
Objectives/Endpoints:
Primary
To test the hypothesis that LY3451838 is superior to 
placebo in the prevention of migraine in 
treatment -resistant migraine patientsThe mean change from baseline in the number of
monthly migraine headache days during the 1-mo nth 
treatment phase (epi[INVESTIGATOR_33176]) a
Secondary
To compare LY3451838 with placebo with respect to 
prevention of monthly headache daysThemean change from baseline in the number of 
monthly headache days during the 1-month treatment 
phase
To compare LY3451838 with placebo with respect to 
50% response rateThe percentage of patients with ≥50% reduction from 
baseline in monthly migraine headac he day s during the 
1-month treatment phase
To evaluate the safety and tolerability of a single dose 
of LY3451838 in treatment -resistant migraine patientsTEAEs
SAEs
To characterize the pharmacokinetics of LY3451838 
following a single IV dose in treatment -resistant 
migraine patientsLY3451838 C maxand AUC
Abbreviations: AEs = adverse events; AUC = area under the concentration -time curve from time 0 to infinite; 
Cmax=maximum observed drug concentration ; ECGs =electrocardiograms; SAEs =serious adverse e vents; 
TEAEs =treatment -emergent adverse events
aEpi[INVESTIGATOR_229156] 4 to 14 migraine headache days and <[ADDRESS_275721] 8 are migraine .
Summary of Study Design:   
Study LAJB i s a mul ticenter, randomized, double
-blind, parallel, placebo -controlled study  of 
LY3451838 in patients who meet the International Classificat ion of Headache Disorders 
versio n3 (ICHD -3) cri teria for a di agnosis of migraine wit h or without aura, or ch ronic 
migraine, and who have previously failed [ADDRESS_275722] -of-care treatm ents for 
migraine prevent ion. The study  has 4 periods, including the screening period, baseline for 
J1H-MC-LAJB( b)Clinical Protocol Page 9
LY3451838eligibilit y, doubl e-blind treatment phase, and follow-up assessme nt of headache epi[INVESTIGATOR_229157].
Treatment Arms and Duration:   
The study  has 2treatment arms: LY3451838 (1500 mg int ravenous [IV]) and matching placebo.
Following a 4-week prospective baseline period, eligible patients will be stratified by [CONTACT_229178] (epi[INVESTIGATOR_160348]) and then rando mly assigned in a 1:[ADDRESS_275723] the study  drug administrati onfor safety  assessment . 
Number of Patients :
The study  will screen an est imated 110potential patients to ensure rando mizat ion of 
approximately  60 migraine pat ients, of which approximately 30patients with chronic migraine.
Statistical Analysis:
A Bayesian analysis for the primary  endpoint will be performed using an analysis o f covariance 
(ANCOVA). The ANCOVA model for the change fro m baseline in the monthly number of 
migraine headache days will include terms for treatment andtype of migraine, and baseline 
number of migraine headache days as a covariate will be used.
Frequent ist analyses for change from baseline in the monthly number of migraine headache days 
and change fro m baseline in the mo nthly number of headache days will be performed using the
same ANCOVA model .
Com parisons between the treatments in rate of responders will be conducted using Cochran 
Mantel  Haenszel tests that are stratified by [CONTACT_229179].
For continuous variables, descriptive statist ics will include the number of patients, mean, 
median, standard deviat ion, minimum, and maximum. Categorical variables will be summarized 
using the number and percentage of patients.
J1H-MC-LAJB( b)Clinical Protocol Page 10
LY34518382.Schedule of A ctivities
J1H-MC-LAJB( b)Clinical Protocol Page 11
LY3451838Table LAJB 2.1 Schedule of A ctivities
Screening Baseline Treat ment Phase Follow-up ED b
(Target) Interval (days) since previous visit - - 30 15 15 15 15 15 15 30 30
Allowable range (days) between visits 3-90 30-40 a
Interval allowance (days) +5 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±[ADDRESS_275724] (WOCBP only) or FSH X
Urine pregnancy test (WOCBP only) h X P X X X X X X
HIV, hepatitis B and C X
Hematology ,chemistry i(include eGFR) X X P X X X X X X X X X
Creatine kinase (Total CK) X P X X X X X
HbA1c P X
Urinalysis X X P X X
P X X
ePRO and headache medication log training X
Inclusion and exclusion criteria X X P
ePRO daily patient diary entry X X X X X X X X
Headache medication log X X X X X X X X
X X X X X X X X
X X X X X X X X
Randomization P
Study drug administration X
MSQ v2.1 X X X X
HIT-6 X X X X
CCI
CCI
CCI
J1H-MC-LAJB( b)Clinical Protocol Page 12
LY3451838Screening Baseline Treat ment Phase Follow-up ED b
(Target) Interval (days) since previous visit - - 30 15 15 15 15 15 15 30 30
Allowable range (days) between visits 3-90 30-40 a
Interval allowance (days) +5 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±[ADDRESS_275725] Visit X X X X X X X X X X X
Self-Harm  Supplement Form X X X X X X X X X X X X
Self-HarmFollow -up Form k X X X X X X X X X X X X
Cogstate Brief BatterylX P X X X X
AEm/ Concomitant medications X 
PK sample n P, EOI, 3h X X X X X X X X X
Immunogenicity samplen P X X X X X
PACAP sample P, EOI, 3h X X X X X X X X X
IRR/ Hypersensitivity sampleo
IRR/Hypersensitivity Follow -up Form p
Pharmacog enetic sample P
Biomarker sample (serum and plasma) P X
Abbreviations: AE = adverse event; ANCA = anti-neutrophil cy toplasmic antibody ;  
ECG =electrocardiogram; ED = early discontinuation; eGFR: estimated glomerular filtration rate; EOI = end of 
infusion; ePRO =electronic patient -reported outcomes ; ; h = hours after end of infusion;
HbA1C =glycosylated hemoglobin; HIT-6= Headache Impact Test -6; HIV =human immunodeficiency virus; IRR =infusion related reaction; 
MSQ =Migraine -Specific Quality of Life Questionnaire ; P= predose assessment; PK =pharmacokinetic; PACAP = pi[INVESTIGATOR_159737] -activating 
polypeptide; WOCBP = women of child -bearing potential
aThe eligibility period of the prospective baseline assessment will last from 30 to 40 days. Investigators and patients may ha ve up to an additional 5 days to 
schedule their Visit 3 appointment (beyond the 40 days); however, eligibility will be based on the [ADDRESS_275726] etephysical examination at screening, Visit 11 and ED. Target edphysical examination to be performed at the remaining visits, which include s
examination of skin, lungs,and skeletomuscular system ; symptom-driven physical examination may also be performed at these visits based on PI [INVESTIGATOR_9106]. 
CCI
CCI
CCI
J1H-MC-LAJB( b)Clinical Protocol Page 13
LY3451838dHeight collected at Visit 1 only.
eIncludes substance usage (dr ugs, alcohol, tobacco, and caffeine ) and family history of premature cardiovascular disease.
fIncludes body temperature, sitting blood pressure, and pulse . Predose vital signs should be taken approximately [ADDRESS_275727] for confirmation.
iChemistry should be collected in a fasting state.
jWearing of the device and entering data in the exploratory app is expected u nless an ex emption is allowed by [CONTACT_229180].
kRequired if triggered by [CONTACT_47584] -Harm Supplement Form per instructions .
lFor the Cogstate Brief Battery, two pre -baseline familiarization assessments will be conducted at Baseline/Visit 2, with at least [ADDRESS_275728]-treatment samples (up to 3) will only be collecte d in patients who experience moderate to sever einfusion reactions or hypersensitivity reactions (as 
defined in Section s7.6.1 , [IP_ADDRESS] , and [IP_ADDRESS] ).
pRequired if triggered by a suspected systemic allergic/hypersensitivity reaction .
qIn event of suspected vasculitis (Section [IP_ADDRESS] ) evaluations may include ANCA, LY concentration, and immunogenicity samples. Skin biopsy may also be 
considered.
J1H-MC-LAJB( b)Clinical Protocol Page 14
LY34518383.Introduction
3.1. Study Rationale
The purpose of Study  J1H-MC-LAJB (LAJB ) is to assess the efficacy and safet y of LY3451838 
in a treatm ent-resistant epi[INVESTIGATOR_229158] c migraine populati on. Blocking calci tonin 
gene-related pepti de (CGRP) has been shown to reduce the migraine burden in both migraine 
phenoty pes, including patie nts who had not responded to other anti -migraine prevent ive drug 
classes. T reatment resistant popul ation, in thi s study , will  be defined as previous failure to 
respond to [ADDRESS_275729] -of-care migraine preventive medicat ions either due to 
inade quate efficacy  and/or due to safet y/tolerabilit y reasons , including the new anti- CGRP 
medicat ions. 
Addit ional rat ionale for the study  design is provi ded in Sect ion 5.4.
3.2. Background
According to the global burden of disease study , among [ADDRESS_275730] in global sequelae prevalence, behind 
dental  caries of permanent teeth and tensio n -type headache; and as the eighth in global years 
lived with disabilit y(Vos et al . 2012) .  
No approved migraine prevent ive treatm entcompletely blocks the onset of migraine attacks. A 
substant ial number of patients does not improve satisfacto rily and/or is burdened wit h 
unacceptable side effects with a significant impact on productivit y and qualit y of life. 
(Blumenfeld et al . 2011; Lanteri -Minet et al . 2011; Abu Bakar et al. 2016). Approximately  43% 
of the pati ents have a history  of previ ous p revent ive medicat ion failure or treatm ents switching . 
(Pi[INVESTIGATOR_110069] .2016).   
Pi[INVESTIGATOR_229159] -activating peptide -38 (PACAP -38) is a pepti de bel onging to the 
secretin/glucagon/
vasoactive intest inal pept ide (VIP)superfamily and is widely  expressed in 
nociceptive pathways withinthe central  and peri pheral  nervous systems (Jolivel et al. 2009; 
Vaudry  et.al 2009 ). There i s evidence to suggest that PACAP -38 is invo lved in migraine 
pathophysio logy.Contrary  to VIP, intravenous PACAP -38 i njecti ons provo ke migraine -like 
attacks in migraineurs (Schy tz et al . 2009). The pl asma l evels o fPACAP -38 (Tuka et al. 2013) 
rise during migraine attacks (Zagami et al. 2014) , suggesting an associat ion between the plasma 
PACAP -38levels and migraine epi[INVESTIGATOR_1841]. 
LY3451838 is a  that 
potently  and select ively binds and neutralizes PACAP. In the preclinical pharmaco logy studi es, 
LY3451838 demonstrated select ive binding and prevent ion of PACAP act ivities. The general 
toxicity of LY3451838 was assessed in 8 -week rat and mo nkey studies and reproductive and 
developmental toxicit y was assessed in rats (male and female fertility) and in pregnant rats and 
rabbits (embryo fetal devel opment). 
Safety, tolerabilit y and pharmacokinet ics of LY3451838 were evaluated in a single ascending 
dose study  in healthy subjects wi thin a dose range of 25 to 1500 mg administered intravenously  
CCI
J1H-MC-LAJB( b)Clinical Protocol Page 15
LY3451838(IV), or a single subcutaneous (SC) dose of [ADDRESS_275731] igator’s Brochure (IB). 
3.3 Benefit/Risk Assessment
LY3451838 i s being developed as a novel therapy  for migraine prevent ion, as PACAP was 
hypothesized as another mediator ofmigraine attacks. Preclinical pharmaco logy data indicated 
that LY3451838 bound and prevented PACAP activit ies in vit ro. 
 
These 
data support testing the efficacy  of LY3451838 in patients with trea tment-resistant migraine.
More informat ion about the known and expected benefits, risks, SAEs and reasonably 
anticipated AEs of LY3451838 are to be found in the IB.
CCI
CCI
CCI
J1H-MC-LAJB( b)Clinical Protocol Page [ADDRESS_275732] the hypothesis that a single IV dose of 
LY3451838 is superior to placebo in the prevention of 
migraine in treatment -resistant migraine patientsThe mean change from baseline in the number of
monthly migraine headache days during the 1-mo nth
treatme nt phase (epi[INVESTIGATOR_33176]) a
Secondary
To compare LY3451838 with placebo with respect to 
prevention of monthly headache daysThe mean change from baseline in the number of 
monthly headache days during the 1-month treatment 
phase
To compare LY3451838 with placebo with respect to 
50% response rateThe percentage of patients with ≥50% reduction from 
baseline in monthly migraine headache days during the 
1-month treatment phase
To evaluate the safety and tolerability of a single dose 
of LY345183 8 in treatment -resistant migraine patientsTEAEs
SAEs
To characterize the pharmacokinetics of LY3451838 
following a single IVdose in treatment -resistant 
migraine patientsLY3451838 C maxand AUC
Exploratory
CCI
J1H-MC-LAJB( b)Clinical Protocol Page 17
LY3451838Abbreviations: AUC = area under the concentration -time curve; CAS =Cranial Autonomic Symptoms ; 
Cmax=maximum observed drug concentration; HIT-6 = Headache Impact Test; MSQ = Migraine Specific 
Quality  of Life Questionnaire; SAEs = serious adverse events; TEAEs = treatment -emergent adver se events; 
TE-ADA = treatment -emergent antidrug antibody
aEpi[INVESTIGATOR_229156] 4 to 14 migraine headache days and <[ADDRESS_275733] 8 are migraine .
CCI
CCI
J1H-MC-LAJB( b)Clinical Protocol Page 18
LY34518385.Study  Design
5.1. Overall Design
Study LAJB i s a mul ticenter, randomized, double- blind, parallel, placebo -controlled study  of 
LY3451838 in patients who meet the International Classificat ion of Headache Disorders
versio n3 (ICHD -3) cri teria for a di agnosis of migraine wit h or without aura, or chronic 
migraine, and who have previously failed [ADDRESS_275734] -of-care treatm ents for 
migraine prevent ion. The study  has 4 periods as described below .
Figure LAJB 5.1illustrates the study  design.
Study Period I (Screening) :The study  and potential risks will be explained to the patient at 
Visit 1. The informed consent form (ICF) must be signed before any study procedures are 
perform ed, which includes discont inuing excluded medicat ions. Pati ents are requi red to 
discontinue all excluded medicat ions or treatments for migraine prevent ion at l east [ADDRESS_275735] 3 months prior to Visit 2. Nerve blocks or devi ce use, such as transcranial 
magnet ic stimulat ion,in the head or neck area for migraine preve ntionarenot allowed within 
30days before Vi sit 2.  
The screening visit (Visit 1) will consist of a full clinical assessment ( see Schedule o f Activities, 
Secti on 2). Visi t [ADDRESS_275736] scheduled procedure of the screening 
assessment for the patient is completed.
Study Period II (Baseline) :Qualified pat ients will enter Study Period II (prospective baseline) 
to determine their eligibilit y for the study  and to establish baseline data for comparison of 
endpo ints during the treatment phase . Beginning at Visit 2, pati ents will  log in daily to th e 
electroni c pat ient-reported outcomes (ePRO) system to answer questions about the occurrence of 
headaches, headache duration, headache features, severit y of headache, and 
whether any  acute
headache medicat ionwas taken .At Visit 2and if available , pati ents will  receive the devices 
requi red for digital biomarkers assessments as well as the necessary  instructi ons and training. 
Also beginning at Visit 2, patients will record the name, dose, and date of any  acute headache 
medicat ion on a headache medication l og which will  be returned to si te staff at each study  visit.
At the end of the prospective baseline period, sites will be notified whether their pat ient met 
criteria and are eligible to be randomized at Visit 3.
To avoid biased reporting, patients must not be told the number of migraine or headache 
days on which study qualification is based.
Study Period III (Double -Blind Treatment): At the start of the 1-monthdouble -blind 
treatm ent phase (Visit 3), patients meet ing all eligibilit y requi rements will be stratified by t ype of 
migraine (epi[INVESTIGATOR_160348]) and then rando mly assigned in a 1:1 ratio within each stratum to 
receive a single dose of LY3451838 or placebo .
Patients will  be given IV study  drug (LY3451838 or placebo) at the study site .Patients will  
continue to log in and co mplete the ePRO diary each day. Pat ients may cont inue to take their 
J1H-MC-LAJB( b)Clinical Protocol Page 19
LY3451838allowed acute migraine headache medication (with some limitat ions; see Section 7.8) during the 
treatm ent phase and will continue to record this use . 
Study Period IV (Follow -up):Patients who complete the double -blind treatment phase (Study  
Period III) will be followed for safety  for [ADDRESS_275737] 
safet y assessed, including daily  com pletion of the ePRO diary and recording of acute headache 
medicat ion use (see Schedule of Act ivities, Section 2). 
Figure LAJB [ADDRESS_275738] epi[INVESTIGATOR_17730]
(defined as 4 to 14 migraine headache days and <15 headache days per 1-monthperiod in the 
prospective baseline period) . To ensure an appropriate balance of pat ients with epi[INVESTIGATOR_39751] c and 
chroni c migraine, the sponsor will stop enrollment of patients with chronic migraine if the 
number of patients exceeds approximately 50%. Chronic migraine will be defined as at least 
15headache days per 1-monthperiod in the prospective baseline period, of which at least [ADDRESS_275739] igator’s assessment.
5.3. End of Study Definition
End of the study is the date of the last visit or last scheduled procedure shown in the Schedule o f 
Activities(Secti on 2) for the last patient .

J1H-MC-LAJB( b)Clinical Protocol Page [ADDRESS_275740] efficacy o f migraine prevent ive medicat ions by [CONTACT_229181] (IHS ;Tfelt-Hansen et al. 2012 ). In line with the recommendat ions for migraine clinical 
trials, we include a [ADDRESS_275741] treatm ent-resistant patients.
The safet y / tolerabili ty of LY3451838 has previously been assessed in a Ph ase 1 study  (LAJA). 
Study  LAJB will enable a clinical assessment of LY3451838 in a treatment -resistant migraine 
patient popul ation, including pat ients who may potent ially have f ailed up to [ADDRESS_275742]
-of-care migraine prevent ives. Tr eatment resistance is more prevalent 
among pat ients with chronic migraine than epi[INVESTIGATOR_49564]; however, the epi[INVESTIGATOR_229160] (ie, 
4 to 14 migraine headache days and fewer than 15 headache days per month) is the most 
commo n, wi th approximately 7% of the migraine populat ion suffering from the chronic form (ie, 
at least [ADDRESS_275743] 8 a re migraine ; Buse et al. 2012; 
Katsarava et al. 2012; Blumenfeld et al. 2013; ICHD -3 2018). 
5.5. Justification for Dose
The pl anned LY3451838 dose for this study  is  IV  for a 60 -kg individual) . 
This dose is selected based on the available preclinical pharmacol ogy, toxicol ogy,and clinical 
data.
Based on the  model, the predicted therapeutic concent ration of  
LY3451838 is approximately    In Study LAJA theobserved plasma concentration of 
LY3451838 [ADDRESS_275744] dose administered in the single ascending dose study, LAJA. 
Interim analysis o f the ongoing LAJA study  suggested that LY3451838 was well -tolerated after 
a single IV dose up to  No dose -limit ing toxicit y was i dentified in this study , and no 
evidence of immune co mplex disease or vasculit is was observed. Vital signs and safety  
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
J1H-MC-LAJB( b)Clinical Protocol Page 21
LY3451838laboratory  tests were al so unremarkable. The available safet y / tolerabilit y data fro m the ongoing 
study  LAJA suppor tthe administration o f single IV dose in Study  LAJB.
This dose is also supported by  [CONTACT_229182].  
 
summarized in IB Section 4.2) .  
 
 
 
 
Based on the available toxicology  and limited clinical  data, thi s dose is acceptable in this 
single- dose efficacy study .
CCI
CCI
CCI
J1H-MC-LAJB( b)Clinical Protocol Page [ADDRESS_275745] ive criterion :
1.Are 18 to 75 y earsof age (incl usive).
2.Have a diagnosis of migraine as defined by [CONTACT_41997] -3 gui delines (1.1, 1.2 .1.1, or 1.3) 
(ICHD -3 2018), with a history  of migraine headaches of at least [ADDRESS_275746] 3 m onths (docum ented by  [CONTACT_229183]’s confirmat ion).
4.From  Visi t 2 to 3 (prospective baseline period) , 
have a frequency of [ADDRESS_275747] fulfillcriteria for migraine.
5.From  Visi t 2 to 3 (prospective baseline period), must achieve suffici ent com pliance wi th 
ePRO daily  headache entries as demonstrated by  [CONTACT_229184] 80% of daily diary  
entries.
6.Prior to Vi sit 1, have docum entati on (by  [CONTACT_229185]’s 
confirmat ion) of previous failure of [ADDRESS_275748] 10 years due to inadequate efficacy (that is, 
maximum tolerated dose for at least 2 months , (3 m onths in case of Botulinium toxin A or B ) 
and/or safet y/tolerabili tyreasons:
a.Propranolo l or metoprol ol
b.Topi [INVESTIGATOR_052]
c.Valproate or divalproex
d.Amitri ptyline or nortri ptyline
e.Flunarizine
f.Candesartan
g.Anti-CGRP ant ibodies (either ligand or receptor)
h.Botulinium toxin A or B (if documented that botulinium toxin was taken for chroni c 
migraine)
i.Rimegepant ODT
j.Atogepant
7. Are available and willing to give signed informed consent.
8.Are reliable and willing to fo llow study  procedures.
9.Women of child- bearing potenti al must test negative for pregnancy  prior to ini tiation of 
treatm ent as indic ated by  a negative serum pregnancy test at the screening visit followed by  a 
negat ive urine pregnancy test within 24 hours prior to exposure.
J1H-MC-LAJB( b)Clinical Protocol Page [ADDRESS_275749] inent (if this is co mplete abst inence, as their 
preferred and usual lifest yle) or in a same sex relatio nship (as part of their preferred and 
usual lifest yle) must agree to either remain abst inent or agree to avoid sexual relat ionships 
with males. Peri odic abstinence (eg, calendar, ovulation, symptothermal, post -ovulation 
methods), declaration of abst inence just for the duration of a trial, and withdrawal are not 
acceptable methods of contraception.
11. W omen of child -bearing potenti al who are not abstinent , as defined above, must agree to use 
one highly effect ive method (l ess than 1% failure rate) of contraception, or a combinat ion of 
two effect ive methods of contraception for the ent irety of the study as well as [ADDRESS_275750] include use of a spermicide. It should be noted that 
the use of male and female condo ms as a double barrier method is not considered acceptable 
due to the high failure rate when these methods are combined.
12.Women not of child -bearing potential may part icipate and include those who are:
a.infertile due to surgical sterilizat ion (hysterectomy, bilateral oophorectomy, or tubal 
ligation), congenital ano maly such as m ullerian agenesis; or
b.post-menopausal –defined as either
i.awom an at l east [ADDRESS_275751] 1 year without an alternative 
medical cause, and a follicle -stimulating horm one >40 m IU/mL; or
ii.awom an [ADDRESS_275752] 12 m onths 
ofspontaneous amenorrhea; or
iii.awom an at l east [ADDRESS_275753] any  personal medical data related to the study  or information related to the 
study  on any  websi teor soci al media si te (eg, Facebook, Twi tter, LinkedIn, YouTube, 
Instagram , etc.) excluding the patient’s personal health care providers’ site(s) until the entire 
study has co mpleted.
15.Men, regardless of their fertilit y status, with non -pregnant wom en of child- bearing potential
(WOCBP )partners must agree to either remain abstinent (if this is their preferred and usual 
lifest yle) or use condoms plus one addit ional highly  effect ive (less than 1% failure rate) 
method of contraception (such as combinat ion oral contraceptives, implanted contraceptives 
or intrauterine device) or effective method of contraception, (such as diaphragms wit h 
J1H-MC-LAJB( b)Clinical Protocol Page 24
LY3451838spermicide or cervical sponge) for the duration o f the study as well as 5 months after study  
drug administration.
a.Men and their partners may  choose to use a double –barrier m ethod of contraception. 
(Barrier protection methods without concomitant use of a spermicide are not an 
effect ive or acceptable method of contracepti on. Thus, each barrier method must 
include use of a spermicide. It should be noted however that the use of male and 
female condo ms as a double barrier method is not considered acceptable due to the 
high failure rate when these barrier methods ar e combined .
)
b.Periodic abst inence (eg, calendar, ovulat ion, symptothermal, post -ovulation methods), 
declaration of abst inence just for the duration of a trial, and withdrawal are not 
acceptable methods of contraception.
16.Men wi th pregnant partners should use condoms during intercourse for the duration of the 
study  as well as 5 m onths after study  drug administrati on.
17.Men should refrain fro m sperm  donat ion for the durati on of  the study  as well as 5 m onths 
after study  drug administrati on.
18.Men who are in exclus ively same sex relat ionships (as their preferred and usual lifest yle) are 
not required to use contraception.
6.2. Exclusion Criteria
Patients w ill be excluded fro m study  enro llment if they meet any o f the following cri teria at
Visit 1, unless stated otherwise in respect ive criterion :
19.
Are current ly enrolled in any other clinical study  involving an invest igational product or any  
other ty pe of medical research judged not to be scient ifically or medically co mpat ible with 
this study .
20. H ave part icipated, within the la st30days or 5 -half-lives (whichever i s longer), in a clinical 
study  involving anyinvest igational product. If the half -li
fe of the invest igational product is 
unknown, [ADDRESS_275754] 3 months prior to Visit 2. Nerve blocks or device use (such as 
transcranial magnet ic stimulation or electrical nerve stimulat ion) in the head or neck area for 
migraine treatm ent must be di scont inued at least 30 day s prior to Vi sit 2. Anti- CGRP 
antibodies ( to either ligand or receptor) must be discontinued at least [ADDRESS_275755] in Inclusio n Cri terion # 6 due to inadequate efficacy (that 
is, m aximum tolerated dose for at least 2 months) and/or safet y/tolerabili ty reasons. Previ ous
failures to medicat ions not on the above list will not be considered toward this exclusio n.
J1H-MC-LAJB( b)Clinical Protocol Page 25
LY345183825.History  of cluster headache or migraine subty pes including hemiplegic (sporadic or familial) 
migraine, ophthalmoplegic migraine, retinal migraine, typi[INVESTIGATOR_229161], 
complicat ions of migraine and migraine with brainstem aura (basilar -type migraine) defined 
by [CONTACT_41997]-3.
26.In the [ADDRESS_275756] other ty pes of  headache besides migraine, 
tension ty pe headache, or m edicat ion overuse headache (MOH) as defined by [CONTACT_41997] -3. 
(In other words, patients can h ave migraine, tensio n type headache, or MOH in the [ADDRESS_275757] other ty pes of  headache in that time.)
27.History  of head or neck injury  within [ADDRESS_275758] reading of electrocardiogram (ECG) at Visit 1 showing abnormalit ies com patible wit h 
acute cardiovascular events and/or serious cardiovascular risk, or have had myocardial
infarction, unstable angina, percutaneous coronary  intervent ion, coronary  artery  by[CONTACT_9292], 
or stroke within [ADDRESS_275759] y. Fridericia -corrected QT interval (QTcF) >45 0 msec for 
males or >[ADDRESS_275760] igator and Lilly Medical prior to 
enrollment.
30.Any liver tests outside the normal range at Vi sit 1 that are clinically significant. Alanine 
aminotransferase (ALT) >2X upper limit of normal (ULN), or total bilirubin (TBL) >1.5X 
ULN, or alkaline phosphatase (ALP) >2X ULN must be discussed and judged not clinically 
significant by  [CONTACT_229186].
31.Evidence of significant active or unstable cogni tive, behavi oral or psychiatric disease by 
[CONTACT_9870] , such as bipo lar disorder, schizophrenia, personalit y disorders, or other 
serious m ood or anxiet y disor ders. Note: Patients with major depressive disorder (MDD) or 
generalized anxiet y disorder (GAD) whose disease state is considered stable and expected to 
remain stable throughout the course of the study , in the opi[INVESTIGATOR_3078] n of the investigator, may be 
considered for inclusio n if they are not on excluded medicat ions.
32.Patients who, in the clinician’s judgment, are actively suicidal and therefore deemed to be at 
significant risk for suicide, or have had clinically significant suicidal ideat ion within the past 
month (eg, includes so me plan or intent to act), or have had any suicidal behavior within the 
past m onth.
33.Women who are pregnant or nursing.
34.Patients who have used opio ids or barbiturate -containing analgesic >[ADDRESS_275761] 3 m onths.
35.History  of drug or al coho l abuse/dependence wit hin 1 y ear pri or to Vi sit 1 (excessive or 
compulsive use as j udged by  [CONTACT_3170]), or currently using drugs of abuse (including 
opi[INVESTIGATOR_2438], barbiturates, and marijuana), or any  prescribed or over -the-counter medication in a 
manner that the invest igator considers indicat ive of abuse/dependence.
36.Have a posit ive urine drug screen for illicit drugs at Visit 1. Prescribed drugs compat ible wit h 
the protocol and not consi dered by  [CONTACT_229187]. Note: A 
retest i s allowed if the urine drug screen is positive for any  prescribed substance or ,if in the 
J1H-MC-LAJB( b)Clinical Protocol Page [ADDRESS_275762] igator site personnel directly affiliated wit h this study  and/or thei r immediate 
families. Immediate family  is defined as a spouse, parent, child, or sibling, whether 
biological  or legally  adopted .
40.Are Eli Lilly and Co mpany empl oyees.
41.Are unwilling or unable to comply wit h the use of data collect ion devices. Wear able di gital 
biomarker device and/or investigational app may be exempted by  [CONTACT_229188] .
42.Have clinically significant proteinuria or hematuria at screening and enro llment .
44.Show evidence of human immunodeficiency virus (HIV) and/or posit ive human HIV 
antibodies ;current hepati tis C infecti on wi th posi tive hepat itis C antibody  and posi tive 
hepat itis C virus RNA ;or hepatit is B and/or positive hepat itis B surface ant igen.
45. Have an abnormal blood pressure (supi[INVESTIGATOR_050]) defined as diastolic blood pressure >95 or 
<50mmHg and/or systolic blood pressure >160 or <[ADDRESS_275763] a history  or presence of serious or unstable illnesses including cardiovascular, hepat ic, 
renal, gastrointestinal, respi[INVESTIGATOR_696] , endocrine, immunol ogic, hematol ogic disease ,
neuro logical (excluding migraine) and other conditio ns that, in the invest igator’s opi[INVESTIGATOR_3078] n, 
could interfere wi th the analyses in t his study , or increase ri sk for study  intervent ion 
administration, or result in a participant’s life expectancy o f <[ADDRESS_275764].
Women of child- bearing potenti aland m enshoul d adhere to the contrac eptive requirement sas 
specified in the protocol (S ection 6.1). No contraception is required for women of non -
child -bearing potenti al, except in com pliance wi th specifi c local government study  requi rements .
6.4. Screen Failures
Individuals who do not meet the criteria for participation in this study  (screen failure) m ay be 
considered for rescreen wit h approval fro m Lilly Medical .
CCI
J1H-MC-LAJB( b)Clinical Protocol Page 27
LY3451838Patients using a c onco mitant m edicat ion that requires a stable dose for a specific durat ion prior 
to Visit 2 may  be rescreened if addit ional time is needed to meet the duration requirement.
Repeat ing of laboratory tests during the screening period does not constitute rescre ening.
J1H-MC-LAJB( b)Clinical Protocol Page [ADDRESS_275765] operation 
procedure, or if an infusion reaction is observed (Secti on 7.6.1 ). Sites m ust have resuscitation 
equipment, em ergency drugs, and appropriately trained medical staff available during the 
infusio n and for at least [ADDRESS_275766] com pleted thei r infusi on. The actual  start and 
stop time of infusio n will be recorded in the electronic data capture (EDC) system . If the infusio n 
is terminated early, this will also be recorded in the EDC.
LY345183 [ADDRESS_275767] is a antibody formulated for IV administration . 
LY3451838 is supplied for clinical trial use as a solut ion in a single -use glass vial. The vial is 
manufactured to deliver  of LY3451838 at . In order to ensure complet e 
withdrawal  and delivery  of the l abel am ount of   of LY3451838 , vials contain an 
approximate 10% volume overfill. The drug product is filled into a glass vial, and sealed wit h a 
stopper and flip- off 2 pi[INVESTIGATOR_229162].
This study  is doubl e-blinded and the placebo prepared at the site by [CONTACT_229189] 0.9% sodi um chloride for inject ion, compendial . This sol ution is 
indist inguishable in appearance fro m the reconstituted active drug solut ion.Study  drug 
preparati on will be con ducted and verified by  [CONTACT_229190]. Study  drug will be 
administered by  [CONTACT_229191].
The unblinded dispensing personnel will receive training and instructions for preparation of each 
dose of LY3451838 and the preparation of the placebo solut ions.
The invest igator or his/her designee is responsible for the fo llowing:
explaining the correct use of the investigational agent(s) to the patient
verifying that instructions are fo llowed properly
maintaining accurate records of investigational product dispensing and co llection
at the end of the study ,returning all unused medication to Lilly, or its designee, 
unless the sponsor and sites have agreed all unused medicat ion is to be destroyed 
by [CONTACT_779], as allowed by [CONTACT_1769] .
7.1.1. Packaging and Labelling
The drug product will be manufactured, tested, packaged, and labeled in accordance with all 
applicable Good Manufacturing Practice (GMP) requirements and country’s regulatory  
requi rements. A certificate of analysis confirming the materials are released for h uman use in 
CCI
CCI
CCI
CCI
CCI
J1H-MC-LAJB( b)Clinical Protocol Page [ADDRESS_275768] igational use only and are 
to be used only within the context of this study .
7.2. Method of Treatment Assignment
Following a 1-monthprospective baseline period, eligible patien ts will be stratified by  [CONTACT_229178] (epi[INVESTIGATOR_160348]) and then rando mly assigned in a 1:[ADDRESS_275769] ratum to 
receive LY3451838 or placebo. Treatment assignment will be determined by a 
computer -generated randomizat ion sequence using an i nteractive web response system (IWRS).
To ensure an appropriate balance o f patients wi th epi[INVESTIGATOR_229158] c migraine, the sponsor will 
stop enrollment of patients with chronic migraine if the number of patients exceeds 
approximately  50%.  
7.2.1. Selection and Timing of Doses
This is a fixed
-dose study where t he single dose of the study drug will be administered at the site
by a trained staff member . The actual time o f dose administration will be recorded in the EDC .
7.3. Blinding
Thisis a double -blind study ; subjec ts, invest igator, and sitepersonnel performing trial related 
activit ies or with the abilit y to influence study  outcom es will  be blinded wi th respect to 
LY3451838 and placebo treatment. To preserve the blinding, only a minimum number of Lilly 
personnel will see the rando mizat ion table and treatment assignments before the study  is 
complete . Site staff who are responsible for drug preparation will not be blinded; laboratory  
personnel will also not be blinded.
After the reporting database is locked for statistical analysis o f the doubl e-blind treatm ent phase, 
a limited number of sponsor personnel will be unblinded to complete the study  report. However, 
any sponsor personnel cont inuing wit h the m anagement and oversight of the study  will rem ain 
blinded to patients’ treatment assignment s.
Emergency  unblinding may be perform ed through the IWRS. This option may be used only if the 
patient’s well -being requires knowledge of the patient’s treatment assignment. All unblinding 
events will be recorded and reported by [CONTACT_8784].
In case of an emergency , the Investi gator has the sole responsibilit y for determining if 
unblinding of a patient’s treatment assignment is warranted for medical management of the 
event. The patient’s safety must always be the first considerat ion in makin g such a 
determinat ion. If the Invest igator decides that unblinding is warranted, it is the responsibilit y of 
the Invest igator to prom ptly document the decisio n and rati onale and notify  Lilly as soon as 
possible.
If an invest igator, site personn el performing assessments, or patient is unblinded, the patient 
must be discont inued fro m the study . In cases where there are ethical reasons to have the patient 
remain in the study , the investigator must obtain specific approval fro m a Lilly Medical for the 
J1H-MC-LAJB( b)Clinical Protocol Page 30
LY3451838patient to continue in the study .During the study , emergency unblinding should occur only by  
[CONTACT_229192] .
7.4. Dosage Modification
Not applicable.
7.5. Preparation/Handling/Storage/Accountability
The invest igator or his/her designee is responsible for the following:
confirming appropriate temperature condit ions have been maintained during 
transi t for all study  treatm ent received and any discrepancies are reported and 
resolved before use of the study  treatm ent.
ensuring that only participants enro lled in the study  may receive study  treatment 
and only  authori zed si te staff may  supply  or administer study  treatm ent. All study  
treatm ents m ust be stored in a secure, environmentally  controlled, and m onitored 
(manual  or autom ated) area i n accordance with the labe led storage condit ions 
with access limited to the invest igator and authorized site staff.
the invest igator, inst itution, or the head of the medical inst itution (where 
applicable) is responsible for study  treatm ent accountabilit y, reconciliat ion, and 
record maintenance (such as receipt, reconciliat ion and final disposit ion records).
Detailed instructions for the preparation and handling of LY3451838 will be provi ded to the 
unblinded site pharmacy personnel by [CONTACT_1034].
LY3451838 for Inject ion vials are tobe stored in refrigerated condit ion (2ºC to 8ºC).
7.6. Special Treatment Considerations
7.6.1. Management of Infusion Reactions
There i s arisk of infusio n react ionswith any bi ological agent ; therefore , allpatientsshoul d be 
monitored cl osely . Symptom s and signs that may occur as part of an infusio n reaction include, 
but are not limited to : fever, chills, nausea, headache, bronchospasm, hypotension, angioedema, 
throat i rritation, rash, pruritus, myalgia, and dizziness. Infusio n site reactions may include 
erythema, induration, pain, pruritus, and edema .In the event that a significant infusio n react ion 
occurs, the fo llowing guidance should be fo llowed:
The drug product infusion should be slowed (for example, reduce infusio n rate by  
50% [for example, an infusion rate of 12 m L/hr becom es 6 m L/hr or sl ower]) or 
stopped based on severit y and in accordance wit h the invest igator’s assessment:
oif slowed, the infusi on shoul d be com pleted at the sl ower rate, as tol erated
oif determined by [CONTACT_229193] n sho uld no l onger continue, no 
further attempts to dose the patient should be made
Supportive care will be administered as determined by  [CONTACT_229194](s)
J1H-MC-LAJB( b)Clinical Protocol Page 31
LY3451838Appropri ate m edicat ion may be used as determined by  [CONTACT_229194](s)
For specific labora tory testing, pl ease see Sect ion9.4.6.[ADDRESS_275770] of allowed/not allowed medicat ions will be co mmunicated to investigators and 
will not constitute a protocol amendment. The concomitant use of acute medicat ions to treat 
migraine is allowed, with so me limitat ions.Treatments used for the prevention of migraine , 
including nutraceuticals and non -pharmaco logical intervent ions,are not allowed at any  time 
during Treatment Phase and Follow -up Phase . Patients should have washed out all migraine 
prevent ive treatments at least 5 day s prior to Visit 2. Botulinum toxin A or B in the head or neck 
area for therapeutic use is not allowed within 3months prior to Visit 2. Nerve blocks or use of 
therapeuti c devices (such as transcranial magnet ic stimulat ion)in the head or neck area or for 
migraine p revent ion arenot allowed within 30 days before Visit 2. Anti-CGRP antibodies (to 
either ligand or receptor) must be discontinued at least 5 half -lives pri or to Visit 2.
Patients will  capture whether they  took any  acute headache medicat ion as part of their daily  diary  
entry  during Treatm ent Phase and Fo llow-up Phase . Acute headache medicat ion name, dose, and 
date will be recorded by  [CONTACT_229195]-up Phase on a headache 
medicat ion log, which will be returned to site staff at each study  visit.  
Table LA JB 7.1 Treatments Allowed and Treatments Not Allowed as Concomitant 
Therapy
A. Medications allowed for the ACUTE treatment of migraine headaches or other pain 
or injury:
Acetaminophen (paracetamol) up to 3000 mg/day , NSAIDs; Triptans; Ergotamine and derivatives; 
Isometheptene mucate, dichloralphenazone and acetaminophen combination (Midrin); or combinations thereof ;
ubrogepant;
The following medications are allowed with restrictions:
1.Opi[INVESTIGATOR_229163] 4days/month.
2.Single dose of injectable steroids allowed only once during the study, in an emergency setting (SP II, III, IV ).
3. Short term use of steroids, < 7days,  for medical circumstances that may arise.
B.Medication s, Procedures or Devices not allowed for any reaso n/indication in Study 
Period II (Baseline) , III (Double -Blind Treatment) , and IV (Follow -up):
ACE inhib itors 
Acetazolamide
J1H-MC-LAJB( b)Clinical Protocol Page 32
LY3451838Acupuncture
Anticonvulsants/Antiepi[INVESTIGATOR_229164] (ARBs)
Beta-blockers 
Botulinum toxin applied to head/neck area for therapeutic use 
Cannabis / Cannabinoids / Cannabidiol
Chiropractic procedures, physiotherapy, TENS or other electric devices on head and neck
Corticost eroids for oral use
Flunarizine
Gabapentin
Herbals with anti -inflammatory effect (feverfew, willow bark, petasites/butterbur)  
Mon oamine oxidase inhibitors (MAOIs)
Memantine
Methy sergide
Nerve block in head/neck area
Oxetorone
Pi[INVESTIGATOR_229165] 5HT2a/2c antagon ists, eg ,trazodone, nefazodone  
Stimulants (prescription strength), eg,methy lphenidate, dextroamphetamine, mixed amphetamine salts
Tizanidine
Tricyclic antidepressants (TCAs)
Triptans for prophylaxis of menstrual related migraine 
Venlafaxine
Verapamil
C.Restricted medication during Study Period III (Double -Blind Treatment )and Study 
Period IV ( Follow -up): Use of the following medications for indications other than 
migraine prevention is allowed providing the dose is stable 2 months prior to V isit 2 and 
is expected to remain stable during the Treatment Phase . 
Benzodiazepi[INVESTIGATOR_229166] -channel blockers (except verapamil , flunarizine , and lomerizine )
Clonidine 
Guanfacine 
Mirtazapi[INVESTIGATOR_229167]/NRIs/SNRIs (other than venlafaxine) 
Use of electric devices (ie ,TENS), physiothe rapy, chiropractic procedures on low back and extremities
D. Restricted medication d uring Study Period IV ( Follow -up):
Medications from List B.
Medications or treatments for migraine prevention.
Medications in List C may now be started, stopped, or have dose modification as long as not being used for 
migraine prevention.
Abbreviations: 5HT = 5 -hydroxy tryptamine; ACE = angiotensin -converting enzyme; NRI = norepi[INVESTIGATOR_120474]; NSAID = nonsteroidal an ti-inflammatory drug; SNRI = serotonin -norepi[INVESTIGATOR_53309] r; SP = Study  Period; SSRI = selective serotonin reuptake inhibitor; TENS = transcutaneous electrical 
nerve stimulation .
7.9. Treatment after the End of the Study
Not applicable.
J1H-MC-LAJB( b)Clinical Protocol Page 33
LY34518388.Discontinua tion Criteria
8.1. Discontinuation from Study Treatment
8.1.1. Permanent Discontinuation from Study Treatment
Possible reasons leading to permanent discontinuatio n of the study  drug :
Unacceptable toxicit y
Patient request
Pregnancy
Discontinuati on due to a hepati c event or liver test abnormalit y:
Patients who are discont inued fro m study  drug due to a hepatic event or liver test 
abnorm ality should have addi tional hepatic safet y data collected and entered into EDC .
oDiscontinuati on of  the study  drug for abnorm al liver tests should be considered 
by [CONTACT_82378] a patient meets one of the fo llowing condi tions af ter 
consultation wit h the Lilly designated medical monitor:
ALT or aspartate aminotransferase (AST) >8X ULN
ALT or AST >5X ULN for mor e than 2 weeks
ALT or AST >3X ULN and TBL >2X ULN or internat ional 
norm alized rati o (INR) >1.5 
ALT or AST >3X ULN with the appearance of fat igue, nausea, 
vomiting, right upper- quadrant pain or tenderness, fever, rash, and/or 
eosinophilia (>5%)
ALP >3X ULN
ALP >2.5X ULN and TBL >2X ULN
ALP >2.5X ULN with the appearance of fatigue, nausea, vo miting, 
right quadrant pain or tenderness, fever, rash, and/or eosinophilia 
(>5%)
If the invest igator, after consultation with the sponsor -designated medical mo nitor, 
determines that a systemic hypersensit ivity react ion has occurred related to study  drug 
administration, the participant should be permanently discont inued from the 
investigat ional drug.
In addit ion, study  drug m ay be discontinued if participants
oanswered “yes”to Questi on 4 or Question 5 on the “Suici dal Ideat ion”porti on of  
the Columbia -Suicide Severi ty Rating Scale ( C-SSRS ), or
oanswered “yes”to any  of the suicide -related behaviors on the Suicidal Behavior 
porti on of  the C -SSRS.
A psychiatrist or appropriat ely trained professio nal may  assist in the decision to 
discontinue the participant.
J1H-MC-LAJB( b)Clinical Protocol Page 34
LY3451838Patients d iscont inuing fro m the study  drug prematurely for any reason should co mplete adverse 
event and other fo llow-up procedures per Section 2(Schedule o f Activities), Section 9.2
(Adverse Events), and Section 9.4(Safet y) of this protocol .
8.1.2. Discontinuation of Ina dvertently Enrolled Patients
If the sponsor or invest igator ident ify a patientwho did not meet enrollment criteria and was 
inadvertent ly enro lled, then the patient should be discontinued fro m study  treatm ent unless there 
are extenuat ing circumstances that make it medically necessary for the patient to continue on 
study  treatm ent. I f the invest igator and the Lilly medical mo nitor agree it is medically 
appropriate to continue, the invest igator must obtain documented approval fro m the Lilly 
medical mo nitor to allow the inadvertent ly enro lledpatientto con tinue in the study  with or 
without treatment with invest igational product. Safety  follow up i s as outlined in Section 2
(Schedule of Act ivities), Secti on 9.2(Adverse Events), and Section 9.4(Safety) of this protocol.
8.2. Discontinuation from the Study
Patients will be discont inued in the fo llowing ci rcumstances:
enrollment in any other clinical study involving an invest igational product or enrollment 
in any other ty pe of medical research judged n ot to be scient ifically or medically 
compatible with this study
participat ion in the study needs to be stopped for medical, safet y, regul atory , or other 
reasons consistent with applicable laws, regulations, and good clinical pract ice (GCP)
investigator dec isionor pati ent request
patients di scontinuing fro m the study  prematurely for any  reason shoul d com plete 
adverse event and other follow -up procedures per Section 2(Schedule of Act ivities), 
Secti on 9.2(Adverse Events), and Section 9.4(Safety) of this protocol.
8.3. Lost to Follow -Up
A patientwill be considered lost to fo llow
-up if he or she repeatedly  fails to return for scheduled 
visits and is unable to be con tacted by  [CONTACT_4145]. Site personnel are expected to make diligent 
attem pts to contact [CONTACT_57986] a scheduled visit or were otherwise unable to 
be followed up by [CONTACT_779].
J1H-MC-LAJB( b)Clinical Protocol Page [ADDRESS_275771] ivities, wi th the study  procedures and their timing (including 
tolerance limit s for timing).
Appendix [ADDRESS_275772] results. Certain samples may  
be retained for a longer period, if necessary, to comply wit h applicable laws, regulat ions, or 
laboratory  certificati on standards.
9.1. Efficacy Assessments
9.1.1. Primary Efficacy Asses sments
ePRO Di ary:Patients will  be asked to use an ePRO instrument to record headache informat ion, 
including report ingfrequency , intensi ty,features (eg, locations and qualit y), and whether any  
acute headache medication was taken .The system also will be used to collect informat ion about
migraine -associated symptoms ( , photophobia, phonophobia, nausea, and/or vomit ing).
9.1.2. Secondary Efficac yAssessments
Secondary  efficacy assessments in this study  (Secti on4) are intended to facilitate the collect ion 
and analysis o f information such as response ( ≥50% reducti on from baseline in the number of 
migraine headache days per mon thand number of mo nthly headache days )with data from  the 
ePRO Di ary (see above), and safet y and tol erabili ty of the study  drug vi a analysis o f TEAEs and 
SAEs.
9.1.3. Appropriateness of Assessments
Theefficacy and safet y assessments used in this study  have bee n well documented and are 
generally regarded as reliable, accurate, and relevant in this patient populat ion
.
9.2. Adverse Events
A clinical trial AE is any untoward medical event associated with the use of a drug or drug 
delivery  system  in humans, whether or not it is consi dered rel ated to that drug or drug delivery  
system .
Invest igators are responsible for monitoring the safety of patientswho have entered this study  
and for al erting Lilly  or its designee to any  event that seems unusual, even if this event may be 
considered an unant icipated benefit to the patient.
The invest igator is responsible for the appropriate medical care of patientsduring the study.
Invest igators must document their review of each laboratory  safety  report and ECG .
The invest igator remains responsible for fo llowing, through an appropriate health care option, 
AEs that are serious or otherwise medically important, consi dered rel ated to the invest igational 
CCI
J1H-MC-LAJB( b)Clinical Protocol Page [ADDRESS_275773] via EDC the occurrence and nature of 
each patient ’s pre -exist ing condit ions, including clinically  significa nt signs and symptoms o f the 
disease under treatment in the study . In addi tion, site personnel will record via eCRF any  change 
in the condit ion(s) and any new condit ions as AEs. Invest igators should record their assessment 
of the potenti al relatedness of e ach AE to protocol procedure or invest igational product via EDC .
The invest igator will interpret and document whether or not an AE has a reasonable possibilit y 
of being related to study  treatm ent, study  device, or a study  procedure, taki ng into account th e 
disease, concomitant treatment , and pathologies.
A “reasonable possibilit y” means that there potentially is a cause and effect relat ionship between 
the invest igational product, study  device ,and/or study  procedure and the AE.
The invest igator will use A E follow-up forms to record addit ional details regarding AEs related 
to injection sites and hypersensit ivity events.
Planned surgeries and nonsurgical intervent ions should not be reported as AEs unless the 
underlying medical condit ion has worsened during t he course of the study .
If a patient ’s study  drug is discont inued as a result of an AE, study  site personnel  must report this 
to Lilly  or its desi gnee via EDC , clarifying if possible the circumstances leading to 
discontinuat ion of treatm ent.
9.2.1. Adverse Event Monitoring with a Systematic Questionnaire
Nonl eading AE collect ion shoul d occur pri or to the collect ion of the C -SSRS.
If a suicide -related event i s discovered during the C -SSRS but was not captured during the 
nonleading AE collect ion, sites shoul d not ch ange the AE form .
If an AE i s seri ous or l eads to discont inuat ion, it needs to be included on the AE form and the 
process for reporting SAEs is fo llowed.
9.2.2. Serious Adverse Events
An SAE is any  AE from this study  that resul ts in one of the fo llowing:
death
initial or prolonged inpatient hospi[INVESTIGATOR_3094]
a life- threatening experience (that is, immediate risk of dying)
J1H-MC-LAJB( b)Clinical Protocol Page 37
LY3451838persistent or significant disabilit y/incapacit y
congenital ano maly/birth defect
important medical events that may not be immediately life -threatening or result in death 
or hospi[INVESTIGATOR_229168].
The study  siteperso nnel must al ert the Lilly , or i ts designee, of any SAE as soon as practically  
possible.
Addit ionally , study  sitepersonnel must alert Lilly , or i ts desi gnee, of  any SAE within [ADDRESS_275774] 
discontinued fro m and/or com pleted the stud y(the pati ent disposi tion EDC has been co mpleted) . 
However, if the Invest igator learns o f any SAE, including a death, at any  time after a patienthas 
been discharged from the study , and he/she considers the event reasonably  possibly  related to the 
study  treatm ent or study  parti cipat ion, the Investigator must promptly notify Lilly. 
Pregnancy (maternal or paternal exposure to the study  drug) does not m eet the definit ion of an 
adverse event. However, to fulfill regulatory  requi rements any pregnancy  should be reported 
following the SAE process to collect data on the outcome for both mother and fetus.
The designated medical mo nitor of  the Sponsor will mo nitor safety  data throughout the course of 
the study . The Sponsor and/or its designee will review SAEs within appropri ate timeframes to 
meet reporting obligat ions imposed by  [CONTACT_3118]. All serious and unexpected AEs 
for this study  will be reported to regulatory  authoriti es in accordance with local laws, direct ives, 
and regulations.
[IP_ADDRESS]. Suspected Unexpect ed Serious Adverse Reactions
Suspected unexpected serious adverse react ions (S[LOCATION_003]Rs) are serious events that are not listed 
in the IB and that the investigator identifies as related to investigational product or procedure. 
Lilly has procedures that will be followed for the ident ificat ion,recording and expedited 
reporting of S[LOCATION_003]Rs that are consistent with glo bal regul ations and the associated detailed 
guidances.
J1H-MC-LAJB( b)Clinical Protocol Page [ADDRESS_275775] the investigator as soon as possible if he or she has a 
complaint or probl em wi th the study  drug so that the situat ion can be assessed.
9.3. Treatment of Overdose
An overdose is not anticipated, as the study  drug will  be administered by  a trained staff member.
In case of overdose, use supportive therapy. There is no known ant idote to LY3451838 overdose.
9.4. Safety
Planned time po ints for all safet y assessments are provided in the S chedule of Activities
(Secti on2).
9.4.1. Physical and Neurological Examinations
A co mplete physical examinat ion will be performed at screening and at time of discharge 
(Secti on 2). Targeted phy sical examinat ion of skin, lungs, and skeletom uscular system 
will be performed according to the Schedule o f Activities (Secti on 2).Symptom -driven 
physical examinat ions will be performed if deemed clinically  necessary . 
A co mplete neurological examinat ion will be performed by a physician at the time po ints 
specified in the Schedule of Activities(Secti on2). If abnorm alities are noted at these 
time points, additional examinat ions should be repeated until the participant has returned 
to baseline. The examiner should be familiar with the participant’s baseline examinat ion. 
Mandated elements of the examinat ion include mental status, gait, balance, coordinat ion, 
cranial nerves, sensory  and m otor system s, and reflexes. Work -
upfor participants with 
clinically significant changes in neuro logical examinati ons shoul d be considered. 
Additional neurol ogical examinat ion will be performed as soon as possible, along with 
any other methodical fo llow-ups deemed necessary  by [CONTACT_3170].
9.4.2. Vital Signs
Vital signs will  include body  temperature, sitting blood pressure, and pulse. For each patient, 
vital signs measurements should be conducted according to the Schedule of Act ivities
(Secti on2).
Predose vi tal signs shoul dbe taken approximately 1 hour prior to the schedule ddosing.
Any clinically  significant findings from vital signs measurement that result in a diagnosis should 
be reported to Lilly ,or its designee ,as an AE viaEDC .
9.4.3. Electrocardiograms
For each patient, 
a single 12 -lead di gital ECG should be collected according to the Schedule of 
Activities (Section 2).Electrocardi ogram s shoul d be co llected prior to blood draws and dosing. 
J1H-MC-LAJB( b)Clinical Protocol Page [ADDRESS_275776] ion. Electrocardi ograms m ay be obtained at addit ional 
times, when deemed clinically necessary.
Electrocardiograms will be interpreted by  a qualified physician (the investigator or qualified 
designee) at the site as soon after the time of ECG colle ction as possible, and ideally while the 
patientis still present, to determine whether the patient meets entry  criteria at the rel evant visits 
and for immediate patientmanagement, should any clinically relevant findings be identified. 
If a clinically si gnificant quanti tative or qualitat ive change fro m baseline is ident ified after 
enrollment, the investigator will assess the patientfor symptom s (for example, pal pi[INVESTIGATOR_814], near 
syncope, syncope) to determine whether the patientcan continue in the study . The investigator or 
qualified designee is responsible for determining if any change in patientmanagement i s needed 
and must document his/her review of the ECG printed at the time of evaluation.
[IP_ADDRESS]. Digital Electrocardiogram Storage
Digital ECGs collected from the study  will be el ectronically  transmi tted to a central  ECG 
laboratory  designated by  [CONTACT_11007] . The central  ECG l aboratory  will perform a basic qualit y control  
check (for example, demographics and study  details) then store the ECGs in a database. At a 
futur e time, the stored ECG data may be overread at the central ECG laboratory  for further 
evaluat ion of machine -read m easurements or to meet regulatory  requi rements. 
The m achine -read ECG intervals and heart rate willbe used for data analysis and report writi ng 
purposes unless a cardio logist overread of the ECGs is conducted prior to complet ion of the final 
study  report ,in which case the overread data would be used.
Any clinically  significant findings from ECGs that result in a diagnosis should be reported to
Lilly, or its designee, as an AE via EDC. 
9.4.4. Laboratory Tests
For each patient, laboratory  tests detailed in ( Appendix 2 ) shoul d be conducted according to the 
Schedule of Act ivities (Section 2). 
With the ex cepti on of  laboratory  test resul ts that may  unblind the study , Lilly or i ts desi gnee will  
provi de the invest igator with the results of laboratory  tests analyzed by  a central  vendor . Note 
that any  resul t that m ay unblind a site would not be shared.
Any cli nically  significant findings from laboratory tests that result in a diagnosis should be 
reported to Lilly ,or its desi gnee ,as an AE viaEDC .
9.4.5. Immunogenicity Assessments
At the visit s and t imes specified in the Schedu le of Act ivities (Secti on 2), venous blood samples 
of approximately  
[ADDRESS_275777] ivity of 
the LY3451838. To interpret the results of immunogenicit y, a venous blood sample will be 
J1H-MC-LAJB( b)Clinical Protocol Page 40
LY3451838collected at the same time po intsto determine the plasma concentrations of LY3451838 . All 
samples for immunogenicit y shoul d be taken predose when applicable and possible .
Treatment -emergent ant idrug ant ibodies ( TE-ADAs) are defined in Sect ion 10.3.[ADDRESS_275778] scheduled assessment or discontinuation visit is TE -ADA 
positive, addit ional samples may be taken unt il the signal returns to baseline (ie ,no longer 
TE-ADA posit ive) or for up to [ADDRESS_275779] patient visit, or for a shorter 
period if local  regulat ions and Ethical Review Boards (ERBs) allow, at a facilit y selected by  [CONTACT_103]. The duration allows the sponsor to respond to future regulatory  requests rel ated to the 
study  drug. Any  samples remaining after 15 years will be destroy ed.
9.4.6. Safety Monitoring
Lilly will periodically  review evolving aggregate safet y data wi thin the study  by [CONTACT_82393].
[IP_ADDRESS]. Hepatic Safety Monitoring
If a study pati
ent experiences any o f the following abnorm al liver test resul ts, liver testing 
(Appendix 4 ) shoul d be repeated wi thin [ADDRESS_275780] 
bilirubin, gamma -glutamyl  transferase, and creatine kinase to confirm the abnormalit y and to 
determine if it is increasing or decreasing:
elevated ALT ≥3X ULN
ALP ≥2X ULN
elevated TBL ≥2X ULN 
If the abnormalit y persists or w orsens, clinical and laboratory  monitoring shoul d be ini tiated by  
[CONTACT_229196] m onitor. Moni toring of ALT, AST, 
TBL, and ALP should cont inue unt il levels normalize or return to approximate baseline levels. 
Hepatic Safety Data Collection
Addit ional safet y data should be co llected if 1 or more of the following condit ions occur: 
elevation of serum  ALT to ≥5X ULN on 2 or more consecutive blood tests
elevated serum  TBL to ≥ 2X ULN (except for cases of known Gilber t’s 
syndro me)
elevation of serum  ALP to ≥2X ULN on 2 or more consecutive blood tests
patientdiscont inued fro m treatm ent due to a hepatic event or abnormalit y of liver 
tests
hepat ic event considered to be a nSAE
CCI
J1H-MC-LAJB( b)Clinical Protocol Page [ADDRESS_275781] ion will be assessed 
by [CONTACT_97267]. Routine monitoring o f vital signs wi th regul ar physical examinat ions, 
and laboratory  testing (including hematology , liver and renal testing,  
CCI
CCI
J1H-MC-LAJB( b)Clinical Protocol Page 42
LY3451838, and urine analysis) will be undertaken to assess for the development of 
 serum sickness and other manifestations of t ype [ADDRESS_275782] ions. 
Unscheduled s tored serum  samples for possible immune safet y laboratory  testing (including, but 
not limited to : β-tryptase, total  IgE, immune -complex testing, and cy tokine panel ) shoul d be 
collected approximately  60 to 120 minutes and 4 to 6 weeks after hypersensit ivity reacti ons.
[IP_ADDRESS]. Infusion Reaction
Symptom s and si gns that m ay occur as part of an infusio n reaction include, but are not limited to : 
fever, chills, nausea, headache, bronchospasm, hypotension, angioedema, throat irritation, rash, 
pruri tus, myalgia, and dizziness. Signs and s ymptoms of a local infusio n site react ion may 
include ery thema, induration, pain, pruritus, and edema. In the event that a ninfusio n reacti on 
occur s during the infusion, please see Section 7.6.1 for guidance on administration of remaining 
study  drug , if applicable . In the event that an infusion reaction occurs at any  other time, 
appropriate supportive care and/or medication may be use d as determined by  [CONTACT_229197](s). These adverse events shoul d be captured as specified in Sect ion 9.2.
Unscheduled s tored serum  samples for possible immune safet y laboratory  testing (including, but 
not limited to: β -tryptase, total  IgE, immune -complex testing, and cy tokine panel ) shoul dbe 
collected approximately  [ADDRESS_275783] ions, will be captured in the EDC.
[IP_ADDRESS]. Suicidal Ideation and Behavior Risk Monitoring
Patients being treated with LY3451838 /placebo shoul d be m onitored appropri ately  and observed 
closely  for sui cidal ideat ion and behavior or any  other unusual changes in behavior, especially at 
the beginning and end of the course of treatment, or at the time of dose changes, either increases 
or decreases. Consideration should be given to discontinuing the study medicat ion in patients 
who experience signs of suicidal ideat ion or behavior, fo llowing a ri sk assessment.
Columbia Suici de-Severit y Rating Scale is a scale t hat captures the occurrence, severit y, and 
frequency  of suicidal ideat ion and behavior during the assessment period via a questionnaire. 
The scale was developed by  [CONTACT_229198] (NIMH) trial group (TASA) 
for the purpose of being c ounterpart to the Columbia Classification Algorithm of Suicide 
Assessment (C -CASA) categorizat ion of suicidal events.
CCI
CCI
CCI
J1H-MC-LAJB( b)Clinical Protocol Page [ADDRESS_275784] ivities (Secti on2),venous blood samples 
of approximately  
2mL each will be collected to determine the serum concentrati ons of 
LY3451838.
The actual  date and time of each sampling must be recorded.
Samples will  notbe used to conduct unspecified disease or populat ion genet ic research either 
now or in the future. Samples will be used to investigate variable expos ure or response to study  
drug. Assessment of variable response may include evaluat ion of AEs or differences in efficacy. 
All samples will be coded with the patientnumber. These samples and any  data generated can be 
linked back to the patient only by [CONTACT_154722]. 
Samples will  be retained for a m aximum  of [ADDRESS_275785] patient visit, or for a shorter 
period if local  regulat ions and/or IRBs impose shorter time limits, for the study  at a f acilit y 
selected by  [CONTACT_47551] i ts desi gnee.
CCI
J1H-MC-LAJB( b)Clinical Protocol Page 44
LY3451838
CCI
CCI
J1H-MC-LAJB( b)Clinical Protocol Page [ADDRESS_275786] ivities
(Secti on2).
Migraine
-Specific Quality of Life Questionnaire version 2.1: The Migraine -Specific Qualit y 
of Life Questionnaire versio n 2.1 (MSQ v2.1) is a self -admin istered healt h status i nstrument that 
was developed to address the physical and emotional impact on funct ioning that i s of specific 
concern to individuals suffering fro m migraine headaches. The instrument consists of 14 items 
that address 3 domains: (1) Ro le Funct ion-Restri ctive; (2) Rol e Funct ion-Prevent ive; and (3) 
Emotional Funct ion (Jinghran et al. 1998 b). The restri ctive domain specifically measures 
disabili ty as related to the impact on performance of normal activit ies, wi th the preventive 
domain addressing co mplete funct ional impairment and the emotional do main assessing the 
feelings related to disabling monthly migraine headache days. Responses are given using a 
6-point Likert -type scale, ranging fro m “none o f the time” to “all o f the time.” Raw scores for 
each dom ain are com puted as a sum  of item responses, wi th the collect ive sum providing a total 
raw score that is then converted to a [ADDRESS_275787] ional improvement ( Jinghran et al. 1998a ; 
Marting et al. 2000). The instrument was designed with a 4 -week recall period and is considered 
reliable, valid, and sensit ive to change in functional impairment due to migraine ( Jinghran et al. 
1998b; Bagley  et al. 2012 ).
Six-item Headache Impact Test (HIT
-6):HIT-6is a tool used to measure the impact headaches 
have on patient’s abilit y to function on the j ob, at school , at hom e and in so cial situations. The 
HIT-6 consists of six items: pain, social funct ioning, rol e functioning, vitalit y, cogni tive 
funct ioning, and psycho logical distress. The patient answers each question using one of the 
following 5responses: “never ,”“rarely ,”“sometimes,”“very often,”or “always .”These 
responses are summed to produce a total HIT- [ADDRESS_275788] of headache on the daily life o f the respondent ( Shin et al. 2008). 
A validat ion stu dy showed that the HIT -[ADDRESS_275789] of 
headache on daily  life in both epi[INVESTIGATOR_39751] c and chronic migraine sufferers ( Yang et al. 2011).
CCI
J1H-MC-LAJB( b)Clinical Protocol Page [ADDRESS_275790] imated 110potential patients to ensure rando mizat ion of 
approximately  60 migraine pat ients. Enrollment will be stratified by t ype of migraine, epi[INVESTIGATOR_229169], and pat ients will be randomly assigned to either LY3451838 or placebo in a 1:1 
allocat ionratio within each stratum. Enrollment in the chronic migraine stratum will be capped 
so that no more than approximately 50% of  the randomized popul ation will  be patients with 
chronic migraine. 
The analysis will be conducted using all rando mized patients, and it is assumed that 
approximately  2% of  the pati ent popul ation will  dropout during the [ADDRESS_275791] a  probabilit y that the number of 
monthly migraine headache days wit h LY34 [ZIP_CODE] treatm ent is day s less than the number of 
monthly migraine headache days wit h placebo treatm ent  
Enrolling approximately 60patients who are stratified by  [CONTACT_229199], epi[INVESTIGATOR_229170], and rando mly assigned to either LY3451838 or placebo in a 1:1 allocat ion rati o within 
each stratum will provide approximately  
 
 
 
 
10.2. Populations for Analyses
For purposes of analysis, the following populat ions are defined:
Population Description
Enrolled All patients who sign informed consent
Randomized All patients who are assigned a study treatment. Patients who had no post 
randomization efficacy measure for the parameter being analyzed will be 
excluded. 
Safety All randomized patients who take at least 1 dose of double -blind study 
treatment. Patients will be included in the treatment group they were 
randomized to. In the event of a treatment error, patients will be analyzed 
according to the treatment they actually received.
CCI
CCI
CCI
CCI
CCI
J1H-MC-LAJB( b)Clinical Protocol Page [ADDRESS_275792] oratory  analyses of the data will be 
conducted as deemed appropriate.
SAS ®software versio n 9.[ADDRESS_275793] ical analyses, unless 
otherwise specified.
10.3.2. Treatment Group Comparability
[IP_ADDRESS]. Patient Disposition
A detailed description o f patient disposi tion will be provi dedat the end of the study . All patients
who discont inue from the study  will be i dentified, and the extent of their participat ion in the 
study  will be summarized by  [INVESTIGATOR_24258]. If  known, a reason for their discont inuat ion will be 
given.
[IP_ADDRESS]. Patient Characteristics
The fo llowing pati ent characteri stics at baseline will be summarized by  [INVESTIGATOR_24258].
Dem ographic (age, sex, ethnic ori gin, height, wei ght, body  mass index)
Migraine and/or headache -related meas ures fro m the ePRO diary  per 1-month
baseline period
J1H-MC-LAJB( b)Clinical Protocol Page 48
LY3451838Number of prior migraine prevent ive treatment fa ilures fro m the list in Section 6.1
(Inclusio n Criterion #6):
oFailed 2 m edicat ioncategori es
oFailed 3 m edicat ioncategori es
oFailed 4 m edicat ioncategori es
Medical history and pre-exist ingcondi tions
Medical history  and pre -exist ing condit ions will be summarized by [CONTACT_229200] (SOC).
[IP_ADDRESS]. Concomitant Therapy
The proporti on of  patients who received concomitant medicat ion and acute m edicat ions will be 
summarized.
[IP_ADDRESS]. Treatment Compliance
Any dose reducti on,overdose, or dose delay will be summarized for all treated patients by 
[CONTACT_9084].
10.3.3. Efficacy Analyses
[IP_ADDRESS]. Primary Analyses
The primary  analysis will be performed using an analysis of covariance (ANCOVA) model for 
the change fro m baseline in the monthly number of migraine headache days. The model will 
include rando mized treatment and ty pe of migraine as fixed effects and the baseline number of 
monthly migraine headache days as a covaria te. The analysis will use a non
-inform ative prior for 
the treatment effect. The treatment group means, treatment contrast, and their respective 95% 
credible regions as well as the success criterion will be based on the posterior treatment effect 
distribut ions.
[IP_ADDRESS]. Secondary Analyses
Frequent ist analyses for change from baseline in the monthly number of migraine headache days 
and change fro m baseline in the mo nthly number of headache days will be performed using the 
ANCOVA model. Co mpar isons between the treatme nts in rate of responders will be conducted 
using Cochran Mantel Haenszel tests that are stra tified by [CONTACT_229201]. 
[IP_ADDRESS]. Exploratory Analyses
Details on exploratory  analysis will be provided in the SAP.
10.3.4. Safety Analyses
The safet y and tol erabilit y of t reatm ent will be assessed by  [CONTACT_176181]:
TEAEs
SAEs
AEs leading to discont inuat ion
J1H-MC-LAJB( b)Clinical Protocol Page 49
LY3451838Potenti alhypersensit ivity events
AEs related to injection site react ions
Vital signs
Physical and neurological examinat ions
ECGs
Laboratory  measurements
CBB
The parameters will be listed, and summarized using standard descriptive statist ics. Addit ional 
analysis will be performed as requi red.
10.3.6. Evaluation of Immunogenicity
The f requency and percentage of patients with preexist ing ADA and with TE -ADA+ to 
LY3451838 maybe tabulated . 
Treatment -emergent ADAs are defined as those with a titer 2- fold (1 dilution) greater than the 
minimum required dilut ion if no ADAs were detected at b aseline (treatment -induced ADA) or 
those wi th a 4-fold (2 dilutions) increase in titer compared to baseline if ADAs were detected at 
baseline (treatment -boosted ADA). For the TE -ADA+ pat ients the distribut ion of maximum 
titers may be described. The frequen cy of neutralizing antibodies mayalso betabulated in TE 
ADA+ patients , when available .
CCI
J1H-MC-LAJB( b)Clinical Protocol Page 50
LY3451838The relat ionship between the presence of ant ibodies and the PKparameters and PDresponse
including safet y and efficacy toLY3451838 may be assessed.
10.3.7. Other Analyses
[IP_ADDRESS]. Health Economics
The change from baseline for the treatment phase for MSQ v2.1 and HIT -6will be analyzed .In 
addition, categori cal analyses will be performed. Addi tional details will beprovi dedin the SAP .
[IP_ADDRESS]. Analysis of C -SSRS Data
Suicide-related thought s and behaviors occurring during treatment will be summarized based on 
responses to the C -SSRS consistent with the C -SSRS Scoring and Data Analysis Guide.
Addit ional details will be provided in the SAP.
10.3.8. Interim Analyses
An interim analysis is planned when data from the majorit y of  randomized pat ients have 
completed the 1-month treatment period. The interim efficacy results may be used for internal 
decisio n
-making to tri gger pl anning activit ies associated with the invest igational p roduct. No 
adjustm ent of  Type I error will be performed as the study  will not be stopped for efficacy , and no 
modificati on of  Study  LAJB is expected based on these interim results. The assessment would be 
conducted by  a sponsor assessment committee with a limited number of preidentified team 
members who do not have direct site contact [CONTACT_229202]/validat ion responsibilit ies. Unblinding 
details will be specified in the unblinding plan sectio n of the SAP or in a separate unblinding 
plan docum ent. Inform ation that may  unblind the study  during the analyses will not be reported 
to study  sites or to the blinded study  team  until the study  has been unblinded.
J1H-MC-LAJB( b)Clinical Protocol Page 51
LY345183811. References
[ICHD -3] The International Classificat ion of Headache Disorder, 3rd edit ion. Cephalgia. 
2018;38 (1):1 -211.
Abu Bakar N, Tanprawate S, Lambru G, et al. Quali ty of life in primary headache disorders: A 
review. Cephalgia. 2016;36(1):67 -91.
Bagley  CL, Rendas -Baum R, Maglint e GA, et al . Validat ing migraine -specific qualit y of life 
questionnaire v 2.1 in epi[INVESTIGATOR_33176]. Headache . 2012;52(3):409 -21.
Begasse de Dhaem OAJ, French J, Morrison C, et al. Migraine com orbidity and cogni tive 
perform ance in patients with focal epi[INVESTIGATOR_30989] y. Epi[INVESTIGATOR_41744] . 2019; 97:[ADDRESS_275794] ic medicat ions for epi[INVESTIGATOR_39751] c migraine and chronic migraine: results from the 
second internat ional burden of migraine study  (IBMS -II). Headache . 2013;53(4) :644-55.
Blumenfeld AM, Varon SF, Wilcox TK, et al. Disabilit y, HRQoL and resource use among 
chronic and epi[INVESTIGATOR_160343]: results fro m the International Burden of Migraine Study  
(IBMS). Cephalgia . 2011;31(3):301 -15.
Buse DC, Manack An, Fanning KM, et al. Chronic migraine prevalence, disabilit y, and 
sociodem ographi c factors: resul ts from the American Migraine Prevalence and Prevention 
Study . 
Headache . 2012;52(10):1456- 70.
Cogstate resources page. Cogstate web site. Available at: https://www.cogstate.com/clinical -
trials/co mputerized -cogni tive-assessment/featured -batteri es/. Accessed July  7, 2020. 
Darby  [CONTACT_24226], Pi[INVESTIGATOR_41279], Fredrickson J , et al . Intraindividual cognit ive decline using a brief 
computeri zed cogni tive screening test. Alzheimers Dement .2012; 8(2):95 - 104.
Ferrari  MD, Di ener HC, Ning X, et al. Fremanezumab versus placebo for migraine prevent ion in 
patients wi th dem onstrated failure to up to four migraine prevent ive medication classess 
(FOCUS) : a randomised, double -blind, pl acebo -controlled, phase 3b trial. Lancet . 
2019:394([ZIP_CODE]):1030- 40.
Grau RG . Drug -induced vasculi tis: new insights and a changing lineup of suspects. Curr 
Rheumatol Rep . 2015 ;17(12):1 -10.
Jinghran P, Davis SM, LaVange LM, Miller DW, Helms RW. MSQ: Migraine -specific -quali ty-
of-life quest ionnarie. Further invest igation of the factor structure. Pharmacoeconomics . 
1998;13(6):[ADDRESS_275795] ionnaire. Headache . 1998;36(4):[ADDRESS_275796] ional characterization of pi[INVESTIGATOR_229155] -activating polypept ide receptors in 
the brain of non -human primates. Neuroscience . 2009;160(2):434-51.
Katsarava Z, Buce DC, Manack AN, Lipton RB. Defining the difference between e pi[INVESTIGATOR_39751] c 
migraine and chronic migraine. Curr Pan Headache Rep. 2012;16(1):86 -92.
J1H-MC-LAJB( b)Clinical Protocol Page 52
LY3451838Lanteri -Minet M, Duru G, Mudge M, Cottrell S. Qualit y of life impairment, disabilit y and 
economic burden associated with chronic daily headache, focusing on chronic migraine wi th 
or wi thout m edicat ion overuse: a sy stematic review. Cephalgia. 2011;31(7):837 -50.
Lim YY , Ellis K A, Harrington K , et al . Use of the CogState Brief Battery  in the assessment of 
Alzheimer ’s disease related cognit ive impairment in the Australian Imaging, B iomarkers and 
Lifest yle (AIBL) study. J Clin Exp Neuropsychol .2012; 34(4):345 -358.
Lim,YY , Jaeger J, Harrington K , et al . Three -month stabilit y of the CogState Brief Battery  in 
healt hy older adults, mild cognit ive impairment, and Alzheimer ’s disease: resul ts from the 
Australian Imaging, Bio markers, and Lifest yle-rate of change substudy  (AIBL -ROCS). Arch 
Clin Neuropsychol .2013; 28(4):[ADDRESS_275797] ionnaire (MSQ v2.1). Headache . 2000;40(3):204 -15.
Maruff P , Thom as E, Cysique L , et al . Validi ty of the CogState Brief Battery : relationship to 
standardized tests and sensit ivity to cognitive impairment in mild traumat ic brain injury , 
schizophrenia, and AIDS de mentia complex. Arch Clin Neuropsychol .2009; 24(2):165 - 178.
Pi[INVESTIGATOR_229171], Mutebi  A, Shah N, et al . Factors associ ated wi th a history  of failure and switching 
migraine prophylaxis treatment: an analysis o f clinical practice data from the [LOCATION_002], 
Germ any, [LOCATION_009], and Japan. Value in Health. 2016;19(3):A68.
Reuter U, God sby [CONTACT_33263], Lanteri -Minet M, et al. Efficacy  and tolerabilit y of erenumab in patients 
with epi[INVESTIGATOR_39751] c migraine in who m two-to-four prevent ive treatments were unsuccessful: [ADDRESS_275798] acebo -controlled, phase 3b study . Lancet . 
2018;392([ZIP_CODE]):2280-7.
Schytz HW, Birk S, Wienecke T, Kruuse C, Olesen J, Ashina M. PACAP38 induces migraine -
like attacks in patients with migraine wit hout aura. Brain . 2009;132(Pt 1):[ADDRESS_275799] -6 (HIT -6) scores for migraine 
patients: Thei r relati on to disabilit y as measured from a headache diary . J Clin Neurol . 
2008;4(4):158 -163.
Tfelt-Hansen P, Pascual  J, Ram adan N, Dahlo f C, D'Amico D, Di ener H C, et al . Gui delines for 
controlled trials of drugs in migraine: third edit ion. A guide for invest igators. Cephalalgia. 
2012;32(1):6 -38
Tuka B, Helyes Z, Markovics A, Bagoly T, Szolcsányi J, Szabó N, Tóth E, Kincses ZT, Vécsei 
L, Taj ti J. Al terati ons in PA CAP -38-like immunoreactivit y in the plasma during ictal and 
interictal  periods of  migraine patients. Cephalalgia
. 2013;33(13):1085- 1095.
Vaudry  D, Falluel -Morel  A, Bourgaul t S, Basille M, Burel D, Wurtz O, et al. Pi[INVESTIGATOR_229172] -activating poly peptide and its receptors: 20 years after the discovery. Pharmacol Rev . 
2009;61(3):283 -357.
Vos T, Flaxman D, Naghavi M, et al. Years lived with disabilit y (YLDs) for 1160 sequelae of 
289diseases and injuries 1990 -2010: a systematic analysis for the Globa l Burden of Disease 
Study  2010. Lancet . 2012;380(9859):2163- 96. 
Yang M, Rendas -Baum  R, Varon SF, Kosinski M. Validat ion of the Headache Impact Test 
(HIT -6™) across epi[INVESTIGATOR_33176]. Cephalgia. 2011;31(3):357 -67.
J1H-MC-LAJB( b)Clinical Protocol Page [ADDRESS_275800] ivating polypept ide and 
migraine. Ann Clin Transl Neurol .2014;1(12):1036 -1040.
J1H-MC-LAJB( b)Clinical Protocol Page 54
LY345183812. Appendices
J1H-MC-LAJB( b)Clinical Protocol Page 55
LY3451838Appendix 1. Abbreviations and Definitions
Term Definition
ADAanti-drug antibody
AE adverse event: Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relatio nship with this treatment. An adverse event can therefore be any unfavorable and 
unintended sign (including an abnormal laborator y finding), symptom, or disease 
temporally  associated with the use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product.
ALT alanine aminotransferase
ALP alkaline phosphatase
ANCOVA analy sis of covariance
AST aspartate aminotransferase
AUC area under concentration -time curve
blinding/masking A double -blind study is one in which neither the [patient] nor any of the investigator or 
sponsor staff who are involved in the treatment or clinical evaluation of the patients are 
aware of the treatment received.
CAS Cranial Autonomic Symptoms
CBB Cogst ate Brief Battery
CGRP calcitonin gene -related peptide
Cmax maximum observed drug concentration
compliance Adherence to all study -related, good clinical practice (GCP), and applicable regulatory 
requirements.
CRP C-reactive protein
C-SSRS Columbia Suicide Severity Rating Scale
CV coefficient of variance
dBM digital biomarker
ECG electrocardiogram
EDC electronic data capture system
enroll The act of assigning a patient to a treatment. Patients who are enrolled in the study are 
those who have been assigned to a treatment.
J1H-MC-LAJB( b)Clinical Protocol Page [ADDRESS_275801]
HIV human immunodeficiency virus
IB Investigator’s Brochure
ICF informed consent form
ICH International Council for Harmonisation
ICHD -3 International Classification of Headache Disorders version 3
Ig immunoglobulins
IHS International Headache Society
Informed consent A process by [CONTACT_9444] a patient voluntarily confirms his or her willingness to participate 
in a particular study, after having been informed of all aspects of the study that are 
relev ant to the patient’s decision to participate. Informed consent is documented by 
[CONTACT_3553] a written, signed and dated informed consent form.
IV intravenous
IVRS/IWRS interactive voice -response sy stem/interactive web -response system
MOH medication overuse headache
MSQ Migraine Specific Quality of Life Questionnaire
NOAEL no-observed -adverse -effect -level
PACAP pi[INVESTIGATOR_159737] -activating peptide
PK/PD pharmacokinetics/pharmacodynamics
QTc corrected QT interval
SAE serious adverse event
SAP statistical analysis plan
SC subcutaneous
screen The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study. 
J1H-MC-LAJB( b)Clinical Protocol Page 57
LY3451838S[LOCATION_003]Rs suspected unexpected serious adverse rea ctions
TBL total bilirubin
TE-ADA treatment -emergent antidrug antibody
TEAE Treatment -emergent adverse event: An untoward medical occurrence that emerges 
during a defined treatment period, having been absent pretreatment, or worsens relative 
to the pretreatment state, and does not necessarily have to have a causal relationship 
with this treatment.
ULN upper limit of normal
VIP Vasoactive intestinal peptide
WOCBP Women of child -bearing potential
J1H-MC-LAJB( b)Clinical Protocol Page 58
LY3451838Appendix 2. Clinical Laboratory  Tests
Clinical Laboratory Tests
Hematology Clinical Chemistry
Hemoglobin Serum Concentrations of:
Hematocrit Sodium
Erythrocy te count (RBC) Potassium
Mean cell volume Total bilirubin
Mean cell hemoglobin concentration Direct bilirubin
Leukocytes (WBC) Alkaline phosphatase
Neutrophils, segmented Alanine aminotransferase (ALT)
Lymphocy tes Aspartate aminotransferase (AST)
Monocytes Blood urea nitrogen (BUN)
Eosinophils Creatinine
Basophils Uric acid
Platelets Calcium
Erythrocy te sedimentation rate (ESR) Fasting Glucose
Glycosylated hemoglobin (HbA1c)
Urinalysis Albumin
Specific gravity Cholesterol
pH Creatine kinase ( Total CK)
Protein Estimated glomerular filtration rate (eGFR) b
Glucose C-reactive protein (CRP)
Ketones Complement component 3 (C3)
Complement component 3a(C3a)
Blood Complement component 4a(C4a)
Urine leukocyte esterase a
Pregnancy Test (serum c/urine d/follicle -stimulating hormone e)
Hepatitis B surface antigenf
Hepatitis C antibody f
Human immunodeficiency virusf
Urine drug scre enf
Abbreviations: CKD = chronic kidney disease ; EPI = epi[INVESTIGATOR_8261]; RBC = red blood cells ; WBC = 
white blood cells.
aA positive urine leuko cyte esterase result will require a follow -up sample with microscopic analysis an dpossibly 
a urine culture.
beGFR for serum creatinine calculated by [CONTACT_229203] [INVESTIGATOR_229173] -bearing potential at screening only.
dIn case of a positive result, the pregnancy must be confirmed b y a serum test.
eTo be performed for women of non -child-bearing potential with 6 -12 months of spontaneous amenorrhea at 
screening only.
fTo be performed at screening only.
J1H-MC-LAJB( b)Clinical Protocol Page 59
LY3451838Appendix 3. Study  Governance Considerations
J1H-MC-LAJB( b)Clinical Protocol Page [ADDRESS_275802] igator is responsible for:
ensuring that the patient understands the nature of the study , the potential 
risks and benefits of participat ing in the study , and that thei r parti cipat ion is 
voluntary.
ensuring that informed consent is given by [CONTACT_229204]. This includes obtaining the appropriate signatures and dates 
on the informed consent form (ICF) prior to the performance o f any protocol
procedures and prior to the administration of investigat ional product.
answering any quest ions the patientmay have throughout the study  and 
sharing in a t imely manner any  new informat ion that m ay be relevant to the 
patient’s willingness to continue his o r her participation in the study .
ensuring that a copy  of the ICF is provi ded to the patient and is kept on file.
ensuring that the medical record includes a statement that written informed 
consent was obtained before the patientwas enrolled in the study  and the 
date the written consent was obtained. The authorized person obtaining the 
inform ed consent m ust al so sign the ICF.
Appendix 3.1.[ADDRESS_275803] (ERB) was properly  consti tuted and convened as required by [CONTACT_126171] (ICH) guidelines and other applicable laws and regulations.
Docum entati on of  ERB approval  of the protocol and the ICF must be provided to Lilly  before the 
study  may begin at the investi gative si te(s). Lilly or i tsrepresentatives must approve the ICF, 
including any  changes made by [CONTACT_41429], before it is used at the invest igative site(s). All ICFs 
must be compliant with the ICH guideline on Good Clinical Pract ice (GCP).
The study  site’s ERB(s) shoul d be provided wi th the fo llowing:
the protocol and related amendments and addenda, current Invest igator 
Brochure (IB) and updates during the course of the study
inform ed consent form
other rel evant docum ents (for example, curricula vitae, advertisements)
J1H-MC-LAJB( b)Clinical Protocol Page 61
LY3451838Appendix 3.1. 4. Regulatory Considerations
This study  will be conducted in accordance wit h the protocol and with the:
consensus ethics principles derived fro m internat ional ethics guidelines, including 
the Decl aration of Helsinki and Council forInternational Organizati onsof
Medical Sciences (CIOMS ) Internati onal Ethi cal Gui delines
applicable ICH GCP Guidelines
applicable laws and regulations
Some of the obligat ions of the sponsor will be assigned to a third party.
Appendix 3.[ADDRESS_275804] igators in this clinical tri al should be neuro logists, headache specialists, or other specialists 
with experi ence in headache clinical trials and treating migraine patients .
Appendix 3.1. 6. Protocol Signatures
The sponsor’s responsible medical o fficer will approve th e protocol , confirming that, to the best 
of his or her knowledge, the protocol accurately  describes the pl anned design and conduct of the 
study .
After reading the protocol, each principal invest igator will sign the protocol signature [CONTACT_25327] a copy  of the signed page to a Lilly representative.
Appendix 3.1. 7. Final Report Signature
[CONTACT_221083], indicating agreement 
that, to the best of his or her knowledge, the report accurately describes th e conduct and results 
of the study .
The study  team  will select the CSR coordinat ing investigator. If this invest igator is unable to 
fulfill this funct ion, another investigator will be chosen by [CONTACT_129236].
The spons or’s responsible medical o fficer and statistician will approve the final CSR for this 
study , confirming that, to the best of his or her knowledge, the report accurately describes the 
conduct and results of the study .
Appendix 3.2. Data Quality Assurance
Toensure accurate, complete, and reliable data, Lilly or its representatives will do the fo llowing:
provi de instructi onal materi al to the study  sites, as appropriate
sponsor start -up training to instruct the invest igators and study  coordinators. This 
traini ng will give instruction on the protocol, the complet ion of the CRFs, and 
study  procedures.
make periodic visit s to the study  site
J1H-MC-LAJB( b)Clinical Protocol Page 62
LY3451838be available for consultation and stay  in contact [CONTACT_129237], tel ephone, and/or fax
review and eva luate CRF data and use standard computer edits to detect errors in 
data collect ion
conduct a qualit y review of the database
In addit ion, Lilly or its representatives will periodically check a sample of the patientdata 
recorded against source documents at the study  site. The study  may be audi ted by [CONTACT_229205], and/or regulatory  agencies at any  time. Invest igators will be given notice before 
an audit occurs.
The invest igator will keep records of all original source data. This might include laboratory  tests, 
medical records, and clinical notes. If requested, the invest igator will provide the sponsor, 
applicable regulatory  agencies, and applicable ERBs with direct access to original source 
docum ents.
Appendix 3.2.1. Data Capture System
An EDC system  will be used in this study . The si te maintains a separate source for the data 
entered by  [CONTACT_92363] -provided EDC system , if collected external to the EDC 
system .
Electronic pat ient-reported outcome (ePRO) measures (for example, a diar y) or other data 
reported direct ly by [CONTACT_102] (for example, a rating scale) may  be entered in an ePRO 
instrum ent (f or exam ple, personal  digital assistant [PDA]), or by  [CONTACT_229206] (IRT) at the time the informatio n is obt ained. In these instances where there 
is no pri or wri tten or electronic source data at the site, the ePRO instrument record will serve as 
the source.
If ePRO records are stored at a third party  site, investi gator si tes will  have continuous access to 
the source documents during the study  and will  receive an archival copy  at the end of the study  
for retenti on.
Any data for which the ePRO instrument record will serve to collect source data will be 
ident ified and documented by [CONTACT_140842]’s study file.
Electronic c ase report form data will be encoded and stored in a clinical trial database. Data 
managed by  a central  vendor, such as laboratory  test data or ECG data, will be stored 
electroni cally in the central vendor’s database syst em. Data will  subsequent ly be transferred 
from the central  vendor to the sponsor desi gnated warehouse.
Any data for which paper documentation provided by [CONTACT_92365] i dentified and documented by  [CONTACT_92366]’s study  file.Paper 
docum entati on provi ded by  [CONTACT_229207] , for exam ple,a headache 
medicat ion log on which patients will record their acute headache medication use during the 
study .
J1H-MC-LAJB( b)Clinical Protocol Page [ADDRESS_275805] igator, or the ERB of the study  site
judges i t necessary  for medical, safety , regul atory , or other reasons consistent with applicable 
laws, regulations, and GCP.
Appendix 3.3.2. Discontinuation of the Study
The study  will be di scontinued if Lilly judges it necessary for medical, safet y, regulatory , or 
other reasons consistent with applicable laws, regulat ions, and GCP.
Appendix 3.4. Publication Policy
The publicat ion policy for Study  J1H-MC-LAJB is described in the Clinical Trial Agreement.
J1H-MC-LAJB( b)Clinical Protocol Page [ADDRESS_275806]
GGT Alkaline Phosphatase Isoenzymes a
CPK
Anti -smooth muscle antibody (or anti -actin 
antibody) a
Abbreviations: ALT = alanine aminotransferase; AST = aspi[INVESTIGATOR_82355]; CPK = creatinine phosphokinase; 
GGT = gamma -glutamyl transferase; Ig = immunoglobulin; INR = international normalised ratio; RBC = red 
blood cells; WBC = white blood cells.
aAssay ed by [CONTACT_11007] -designated or local laboratory.
bReflex/confirmation dependent on regulatory requirements and/or testing availability.
J 1 H -M C -L A J B( b) Cli ni c al Pr ot o c ol P a g e 6 5 
L Y 3 4 5 1 8 3 8 A p p e n di x 5. R e c o m m e n d e d L a b or at or y  T e sti n g f or 
H y p er s e n siti vit y  E v e nt s 
La b testi n g s h o ul d be perf or m e d at t h e ti me of  a  S y ste mic H y perse nsit i vit y E v e nt. I m p orta nt 
i nf or m at i o n a b o ut w h y, w he n, a n d w hat t o t es t f o r are pr o vi de d bel o w. T he ma na ge me nt of  t he 
a d verse e ve nt ma y warra nt la b testi n g be y o n d t h at descri be d b el o w a n d s h o ul d be p erf or me d as 
cli nicall y i n dicate d. 
La b orat or y  t esti n g d uri n g a S y ste mic H y perse nsit i vit y E ve nt is n ot perf or me d f o r dia g n ostic 
p ur p oses. Its i nte nt is se veral f o l d: 
T o hel p c haracteri ze a n d cl assif y  s y ste mic h y perse nsit i vit y r e a cti o ns 
T o m eet re g ulat or y  e x pectati o ns 
T o i m pr o ve s u bse q ue nt cli nical ma na ge me nt b y  h el pi n g t o di st i n g uis h bet wee n t he vari o us 
me c ha nist ic bases of a na p h yla xis 
W he n s h o ul d la bs be o btai ne d? 
I n t he prese nce of ge neralize d urticaria or if a na p h yla xis is s us pecte d 
After t h e s u bject has bee n sta bilize d, o btai n a sa m ple wit hi n 1 -2 h o urs of t he e ve nt, h o we ver, 
sa m ples ma y  b e o btai ne d as late as 1 2 h o urs after t he e ve nt as a nal ytes ca n re mai n altere d f or 
a n e xte n de d peri o d of ti me . Rec or d t he ti me at w hic h t he sa m ple was c o llecte d. 
O btai n a f o ll o w u p sa m ple at t he ne xt re g ularl y sc he d ule d visit or after 4 wee ks, w hic he ver is 
later. 
W hat l a bs * s h o ul d be o btai ne d? 
Tr y ptase * * 
A D A a n d L Y c o nce ntrati o n ( P K) 
oA D A testi n g s h o ul d i ncl u de dr u g s pecific I g E or t h e bas o p hil act i vat i o n test ( B A T) #. 
T hese tests are n ot r o uti nel y  a vaila ble a n d nee d t o be de vel o pe d f or i n di vi d ual m olec ules 
base d o n t he ir e v o l vi n g safet y pr ofile. Sa m ples are c ollecte d, a n d testi n g c o n d ucte d o nce 
t h e assa y is a vaila ble, as a p pr o pri ate. Pl ease c o ns ult a n i m m u n ol o gist wit hi n G P S f or 
f urt her g ui da nce. 
C o m ple me nt 
oC 3a a n d C 5a 
C y t o ki nes 
oI L -6, I L -1 β, I L -1 0 ( or a n y c yt o ki ne pa nel t h at i ncl u des t hese 3 c y t o ki nes) 
* t h ese la bs are b u n dle d i n t he Cli nical La b orat or y  O perati o ns H y perse nsit i vit y La b Testi n g Kit 
* * If a tr y ptase sa m ple is o btai ne d m ore t ha n 2 h o urs after t he e ve nt (ie ,wi t hi n 2 t o 1 2 h o urs), or 
is n ot o btai ne d beca use m o re t ha n 1 2 h o urs ha ve la pse d si nce t he e ve nt, o btai n uri ne f or 
J1H-MC-LAJB( b)Clinical Protocol Page 66
LY3451838N-methylhistamine (NMH) testing. Note that f or tryptase serum samples obtained within [ADDRESS_275807] void urine fo llowing the event. Obtain a fo llow up urine for NMH testing at the next 
regul arly scheduled visit or after 4 weeks, whichever is later.
# The BAT is an in vitro cell based assay  that only requi res a serum  sample. It i s a surrogate assay 
for drug specific IgE but is not specific for IgE.
J1H-MC-LAJB( b)Clinical Protocol Page 67
LY3451838Appendix 6. Migraine and Headache Endpoint 
Definitions
Diagnosis Definition/Criteria
Migraine headache Aheadache, with or without aura, o f ≥30 minutes duratio n,with both of the 
following required features (A and B) :
A.At least 2 of the following headache characteristics:
Unilateral location
Pulsating quality
Moderate or severe pain intensity
Aggravatio n by [CONTACT_229208]
B.During headache at least one of the following:
Nausea and/or vomiting
Photophobia and phonophobia
(Definition adapted from the standard IHS ICHD -3 definition)
Probable migraine headache A headache of ≥[ADDRESS_275808] one B 
criteri a.
Migraine headache day 
(primary  objective)A calendar day on which a migraine headache or probable migraine headache 
occurs.
ICHD migraine headache day A calendar day on which a migraine headache occur s.
Migraine headache attack Beginning on any  day a migraine headache or probable migraine headache is 
recorded and ends when a migraine -free day occurs.
Non-migraine headache All headaches of ≥30 minutes duration not fulfilling the definition of migraine 
or probable migraine.   
Non-migraine headache day A calendar day on which a no n-migraine headache occur s.
Headache day A calendar day on which any type of headache occurs (including migraine, 
probable migraine, and non -migraine headache).
Epi[INVESTIGATOR_229174] 14 migraine headache days and <[ADDRESS_275809] 8 are migraine.
Abbreviations: ICHD = International Classification of Headache Disorders; IHS =International Headache Society.
J1H-MC-LAJB( b)Clinical Protocol Page 68
LY3451838Appendix 7. Protocol A mendment J1H-MC-LAJB(b)
Summary
Overview
Protocol  J1H-MC-LAJB, A Phase 2, Rando mized, Double -Blind, Pl acebo -Controlled Study  of 
LY3451838 in Adults with Treatment -Resista nt Migraine, has been amended. The new protocol  
is indicated by  [CONTACT_61504] ( b) and will be used to conduct the study  in place of any  preceding 
versio n of the protocol.
The overall changes and rationale for the changes made to this protocol are described in the 
following table . Other general editorial  correcti ons and formatting changes not affect ing content 
have been made in the document, and these changes are not ident ified in the amendment 
summary table or with strikethrough/underscore.
Amendment Summary for Protocol J1H -MC-LAJB Amendment ( b)
Section # and Name [CONTACT_23688]
1. Synopsis Number of patients updated . Statistical calculations 
confirmed that CSF could 
be achieved with less
patients
5.2  Number of Participants Number of patients updated . Statistical calculations 
confirmed that CSF could 
be achieved with less
patients
6.1 Inclusion Criteria Criteri on6 added
Nortrip tyline
Rimegepant and atogepantFor clarification.
Approved post 
protocol approval
7.8  Co ncomitant Therapy Added short term use of steroids to Table 7.1. To allow short term use 
of steroids
10.1  Sample Size Determination Number of patients updated
Sample size calculation assumptions 
updatedStatistical calculations 
confirmed that CSF could 
be achieved with less
patients
[IP_ADDRESS]   Patient Characteristics Rem oved bullet , “Alcohol, tobacco, caffeine, 
and nicotine consumption” .Said d ata is not being 
collected and thus, will 
not be statis tically 
summarized
10.3.8  Interim Analysis Replaced “all” with “majority of” patients to 
be included in the interim analysis.To clarify what patients 
will be included
J1H-MC-LAJB( b)Clinical Protocol Page 69
LY3451838Revised Protocol Sections
Note: Deletions have been ident ified by [CONTACT_58001] .
Addit ions have been identified by  [CONTACT_58002] .
The numbering system used for inclusio n and exclusion criteria provides a unique number for 
each cri terion and all ows f or efficiency in data collection.
In case an amendment to the protocol adds a criterion, that criterion will receive the next 
available number, regardless of whether it is an inclusio n or excl usion cri terion.
1. Synopsis
Number of Patients :
The study  will screen an est imated [ADDRESS_275810] epi[INVESTIGATOR_41989] (defined as 4 to 14 migrain e headache days and <15 headache days per 1-monthperiod 
in the prospective baseline period ). 
To ensure an appropriate balance of patients with epi[INVESTIGATOR_229175], the sponsor will stop enrollment of pat ients with chronic migraine if the 
number of patients exceeds approximately  50% . Chronic migraine will be defined as at least 
15headache days per [ADDRESS_275811] igator’s assessment.
6.[ADDRESS_275812] documentation (by [CONTACT_229209]’s 
confirmat ion) of previous failure of [ADDRESS_275813] 10 years due to inadequate efficacy (that is, 
maximum tolerated dose for at least 2 months, (3 mo nths in case of Botulinium toxin A or B) 
and/or safet y/tolerabili ty reasons:
a.Propranolo l or metoprol ol
b.Topi [INVESTIGATOR_052]
c.Valproate or divalproex
d.Amitri ptyline or nortri ptyline
e.Flunarizine
f.Candesartan
g.Anti-CGRP ant ibodies (either ligand or receptor)
J1H-MC-LAJB( b)Clinical Protocol Page 70
LY3451838h.Botulinium toxin A or B (if documented that botulinium t oxin was taken for chronic 
migraine)
i.Rimegepant ODT
j.Atogepant
7.8 Concomitant Therapy
Table LA JB 12.1 Treatments Allowed and Treatments Not Allowed as Concomitant 
Therapy
A.Medications allowed for the ACUTE treatment of migraine headaches or other pain 
or injury:
Acetaminophen (paracetamol) up to 3000 mg/day , NSAIDs; Triptans; Ergotamine and derivatives; Isometheptene
mucate, dichloralphenazone and acetaminophen combination (Midrin); or combinations thereof ; ubrogepant ;
The following medications are allowed with restrictions:
1.Opi[INVESTIGATOR_229163] 4 days/month.
2.Single dose of injectable steroids allowed only once during the study, in an emergency setting (SP II, III, 
IV).
3.Short term use of stero ids, < 7day s,  for medical circumstances that may arise.
B.Medication s, Procedures or Devices not allowed for any reaso n/indication in Study 
Period II (Baseline), III (Double -Blind Treatment), and IV (Follow -up):
ACE inhib itors 
Acetazolamide
Acupuncture
Anticonvulsants/Antiepi[INVESTIGATOR_229164] (ARBs)
Beta-blockers 
Botulinum toxin applied to head/neck area for therapeutic use 
Cannabis / Cannabinoids / Cannabidiol
Chiropractic procedures, physiotherapy, TENS or other electric devices on head and neck
Corticost eroids for oral use
Flunarizine
Gabapentin
Herbals with anti -inflammatory effect (feverfew, willow bark, petasites/butterbur)  
Mon oamine oxidase inhibitors (MAOIs)
Memantine
Methy sergide
Nerve block in head/neck area
Oxetorone
Pi[INVESTIGATOR_229165] 5HT2a/2c antagonists, eg ,trazodone, nefazodone  
Stimulants (prescription strength), eg, methy lphenidate, dextroamphetamine, mixed amphetamine salts
Tizanidine
Tricyclic antidepressants (TCAs)
Triptans for prophylaxis of menstrual related migraine 
Venlafaxine
Verapamil
J1H-MC-LAJB( b)Clinical Protocol Page 71
LY3451838C.Restricted medication during Study Period III (Double -Blind Treatment) and Study 
Period IV (Follow -up): Use of the following medications for indications other than 
migraine prevention is a llowed providing the dose is stable 2 months prior to V isit 2 and 
is expected to remain stable during the Treatment Phase . 
Benzodiazepi[INVESTIGATOR_229166] -channel blockers (except verapamil , flunarizine , and lomerizine )
Clonidine 
Guanfacine 
Mirtazap ine 
SSRIs/NRIs/SNRIs (other than venlafaxine) 
Use of electric devices (ie ,TENS), physiothe rapy, chiropractic procedures on low back and extremities
D. Restricted medication d uring Study Period IV (Follow -up):
Medications from List B.
Medications or treatments for migraine prevention of.
Medications in List C may now be started, stopped, or have dose modification as long as not being used for 
migraine prevention.
Abbreviations: 5HT = 5 -hydroxy tryptamine; ACE = angiotensin -converting enzyme; NRI = nor epi[INVESTIGATOR_120474]; NSAID = nonsteroidal anti -inflammatory drug; SNRI = serotonin -norepi[INVESTIGATOR_53309] r; SP = Study  Period; SSRI = selective serotonin reuptake inhibitor; TENS = transcutaneous electrical 
nerve stimulation .
10.[ADDRESS_275814] acebo 
in a 1:1 allocat ion rati o within each stratum . Enrollment in the chronic migraine stratum will be 
capped so that no more than approximately 50% of the rando mized population will be pat ients 
with chroni c migraine. 
The analysis will be conducted using all randomized patients, and it is assumed that 
approximately  2% of  the pati ent popul ation will dropout during the [ADDRESS_275815] a 60% probabilit y that the number of 
monthly migraine headache days wit h LY3451838 treatment is 1.5 day s less than the number of 
monthly migraine he adache days wit h placebo treatm ent (i .e., the success criterion is 
P(LY3451838 -Placebo < -1.5) ≥0.60).
Enrolling approximately [ADDRESS_275816] acebo in a 1:1 allocat ion rati o within 
each stratum will provide approximately 77 94% probabilit y for meeting the success criterion if 
the mean monthly number of migraine headache days with LY3451838 is 2.35 2.57 days less 
than the mean mo nthly number of m igraine headache days wit h placebo for both the epi [INVESTIGATOR_229176] 3.70 days less for the chroni c migraine popul ation.
Assumpt ions in this sample size calculation were based on data from previous Phase 2 and 
Phase 3 studi es wi th galcanezumab in pat ients with epi[INVESTIGATOR_39751] c and chronic migraine. It is assumed 
J1H-MC-LAJB( b)Clinical Protocol Page 72
LY3451838that the baseline mean ( ±standard deviat ion) monthly  migraine headache days will be 9.34
(±2.82) day s for the epi[INVESTIGATOR_39751] c popul ation and 18.65 ( ±4.68) days for the chronic populat ion.It is 
also assumed that the change fro m baseline mean (± standard deviat ion) monthly  migraine 
headache days for placebo will be -0.31 (± 32.50) days for the epi[INVESTIGATOR_229177] 
-2.21 (± 5.273.75) day s for the chronic migraine populat ion. 
[IP_ADDRESS] Patient Characteristics
The fo llowing pati ent characteri stics at baseline will be summarized by  [INVESTIGATOR_24258].
Dem ographic (age, sex, ethnic ori gin, height, wei ght, body  mass index)
Migraine and/or headache -related meas ures fro m the ePRO diary  per 1 -month 
baseline period
Number of prior migraine prevent ive treatment failures fro m the list in Section 6.1
(Inclusio n Criterion #6):
oFailed 2 m edicat ioncategori es
oFailed 3 m edicat ioncategori es
oFailed 4 m edicat ioncategori es
Alcoho l, tobacco, caffeine, and nicotine consumpt ion
Medical history and pre-exist ingcondi tions
10.3.[ADDRESS_275817] or data entry/validat ion responsibilit ies. Unblinding 
details will be specified in the unblinding plan sectio n of the SAP or in a separate unblinding 
plan docum ent. Inform ation that may  unblind the study  during the analyses will not be reported 
to study  sites or to the blinded study  team  until the study  has been unblinded.
Leo Document ID = 8b336ee6-89e8-406f-82d1-a8f32dfbd810
Approver: 
Approval Date & Time: 19-Nov-2021 20:56:50 GMT
Signature [CONTACT_32869]: Approved
Approver: 
Approval Date & Time: 19-Nov-2021 21:03:03 GMT
Signature [CONTACT_32869]: Approved
[COMPANY_003]
[COMPANY_003]